Inhibitors of solute carrier family 6A member 19 (SLC6A19) and methods of use thereof

Abstract

As used herein, a compound of formula (II): TIFF2025534664000956.tif52161, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 12b and X are as defined elsewhere herein. Also provided herein are methods for preparing compounds of formula (II). Also provided herein are methods for inhibiting SLC6A19 and treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 415,590, filed October 12, 2022, U.S. Provisional Patent Application No. 63 / 456,403, filed March 31, 2023, and U.S. Provisional Patent Application No. 63 / 532,327, filed August 11, 2023, the contents of which are incorporated herein by reference in their entireties. [Background technology]

[0002] Solute carrier family 6A member 19 (SLC6A19), also known as B0AT1, is a sodium-dependent neutral amino acid (NAA) transporter primarily expressed on the apical membrane of kidney and intestinal epithelial cells (Fairweather et al. J. Biol. Chem (2015) 290, 24308-24325). In the intestine, surface expression of SLC6A19 is dependent on the chaperone protein ACE2 for amino acid uptake (Singer et al. Am. J. Physiol. Gastrointest. Liver Physiol (2012) 303, G686-G695). In the kidney, SLC6A19 requires TMEM27 for surface expression to reabsorb amino acids (Verrey et al. Arch. Eur. J. Physiol. (2009) 458, 53-60).

[0003] Phenyleketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase (PAH) enzyme, a key enzyme in the metabolism of phenylalanine (Phe) to tyrosine (Tyr), both of which are NAAs. Patients with PKU experience toxic accumulation of Phe in their blood and other tissues, which leads to neurological changes (Scriver CR Hum. Mutat. (2007) 28, 831-843). Treatment options for PKU include drastic restriction of protein intake and two FDA-approved medications, Parinzic and Kuban. However, compliance with the former is poor, and both medications are limited to a small subset of patients, leaving significant unmet medical needs (Strisciugio et al. Metabolites (2014) 4, 1007-1017; Gentile et al. Mol. Genet. and Metab. (2010) 99, S64-S67). Because PKU symptoms result from systemic Phe accumulation, inhibiting SLC6A19 to limit intestinal absorption of Phe and its reuptake into the kidney may be a viable approach for treating PKU. Indeed, loss of SLC6A19 in a mouse model of PKU significantly increased urinary Phe excretion, dramatically reduced plasma Phe, and normalized neurotransmitter levels (Belanger et al. JCI Insight (2018) 3, e121762).

[0004] The prevalence of chronic kidney disease (CKD) is rapidly increasing, with an estimated 15% of the US adult population having CKD (CDC 2021). A loss-of-function splice variant (c.1173+2T>G) (Sveinbjornsson G. et al. Hum. Mol. Genet. (2014) 23, 6935-6943) and a missense variant (D173N) in SLC6A19 have been reported to be associated with protection from CKD (Sinnott-Amstrong N. et al. Nat. Genet. (2021) 53, 185-194).

[0005] Metabolic syndrome and related diseases such as diabetes mellitus are widespread worldwide, with an estimated one-third of US adults suffering from metabolic syndrome (Saklayen M. Curr Hypertens Rep (2018) 20, 12). Mice lacking SLC6A19 exhibit improved metabolic outcomes, including resistance to weight gain on a high-fat diet, improved glucose tolerance and insulin sensitivity, and increased energy expenditure (Jiang et al. Mol. Metab. (2015) 4, 406-417). These positive outcomes may be due to increased secretion of FGF21 and GLP-1, two hormones that play important roles in regulating energy metabolism (Geng et al. Nat Rev Endo. (2020) 16, 654-667, Baggio et al. Mol Metab (2021) 46). Therefore, inhibiting SLC6A19 may be an effective approach for treating metabolic diseases.

[0006] In humans, biallelic loss of function of SLC6A19 causes a rare disorder called Hartnup syndrome, which is largely asymptomatic in adequately nourished patients (Seow et al. Nat. Genet. (2004) 36, 1003-1007; Azmanov et al. Hum. Mutat. (2008) 29, 1217-1221). Because the NAA tryptophan is essential for the synthesis of nicotinamide, Hartnup patients may develop niacin deficiency and associated symptoms, including dermatitis, photosensitivity, and psychosis, which are successfully controlled with niacin supplementation (Hashmi et al. StatPearls (2021)). Similarly, mice with complete loss of SLC6A19 are viable and fertile (Jiang et al. Mol. Metab. (2015) 4, 406-417). Therefore, inhibition of SLC6A19 appears to be a viable therapeutic approach. There remains a need for therapies to treat such diseases / disorders. [Prior art documents] [Non-patent literature]

[0007]

Non-licensed literature 1

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

[0008] In one aspect, provided herein is a compound of formula (II): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, -C(O)C 1~6 Alkyl, C 3~10 Cycloalkyl, -N(R 4 )2, 5- to 20-membered heteroaryl, -C 1~6 alkyl (5- to 20-membered heteroaryl), or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a optionally replaced by R 3 is a 6- to 10-membered heteroaryl, the 6- to 10-membered heteroaryl is unsubstituted; Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, -C1~6 Alkyl (5-20 membered heteroaryl), or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Thioalkyl, C 3~10 Cycloalkyl, C 1~6 haloalkyl, or 5- to 20-membered heteroaryl, wherein R 5 and R 7 C 1~6 Alkyl, C 1~6 Alkoxy, or C 3~10 each cycloalkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 1~6 Alkoxy, C 3~10 Cycloalkyl, -OC 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, 5- to 20-membered heteroaryl, or -(R x )-5 to 20-membered heteroaryl), where each R 8 is one or more R a is optionally replaced by R x is -NH- or -O-, R 10 is, independently for each occurrence, H or D, R 11a and R 11b is independently H or C at each occurrence 1~6 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a Or R 12b Together with one of the 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, Each R a are independently D, -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, -C(O)NH2, -C(O)NH(C 1~6 alkyl), -C(O)N(C 1~6 alkyl) 2, 4- to 10-membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b are independently D, -OH, halo, C 1~6 Alkyl, or C1~6 It is an alkoxy.

[0009] In one aspect, provided herein is a compound of formula (I'): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R4)2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a Or R 12b Together with one of the 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, Each R a are independently -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, -C(O)NH2, -C(O)NH(C 1~6 alkyl), -C(O)N(C 1~6 alkyl) 2, 4- to 10-membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b are independently D, -OH, halo, C 1~6 Alkyl, or C 1~6 It is an alkoxy.

[0010] In one aspect, provided herein is a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 alkyl or R 12a Or R 12b C together with one of 3~10 forming a cycloalkyl, R 12a and R 12bare each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, and Each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 Any embodiment provided herein of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, is also an embodiment of a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0011] In one aspect, provided herein is a compound of formula (IA): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In another variation, m, n, R of formula (IA) 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11band X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0012] In one aspect, provided herein is a compound of formula (IB): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined elsewhere herein. In another variation, m, R of formula (IB) 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined for a compound of formula (I'), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0013] In one aspect, provided herein is a compound of formula (IC): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In another variation, m, n, p, R of formula (IC) a , R 5 , R6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0014] In one aspect, provided herein is a compound of formula (ID): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, q, r, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b In another variation, m, n, q, r, R of formula (ID) are as defined elsewhere herein. a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0015] In one embodiment, a compound of formula (1-E): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n, R a , R 1 , R 3 , R5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In another variation, n, R of formula (IE) a , R 1 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0016] In one aspect, provided herein is a compound of formula (IF): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In another variation, m, n, R of formula (IF) 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0017] In one aspect, provided herein are compounds of formula (IG): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, each R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In another variation, m, n, and each R of formula (IG) 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0018] In one aspect, provided herein is a compound of formula (IH): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, s, t, R 3 , R 5 , R 6 , R 7 , R 9 , R 11a , R 11b , R a , X, Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are as defined elsewhere herein. In another variation, m, n, s, t, R of formula (IH) 3 , R 5, R 6 , R 7 , R 9 , R 11a , R 11b , R a , X, Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is as defined for a compound of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0019] Any embodiment provided herein of a compound of Formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, applies equally, where applicable, to any other formula detailed herein, as if each and every embodiment were specifically and individually listed. Thus, each embodiment provided herein of a compound of Formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, e.g., m, n, R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 11b, and embodiments relating to X include those of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), (I-D3), (IE), (I-E1), (I-E2), (I-E3), (I-E4), (I-E5), (I-E6), (I-E7), (I-E8), (I-E9), (I-E10), (I-E11), (I-E12), (I-E13), (I-E14), (I-E15), (I-E16), (I-E17), (I-E18), (I-E19), (I-E20), (I-E21), (I-E22), (I-E23), (I-E24), (I-E25), (I-E26), (I-E27), (I-E28), (I-E29), (I-E30), (I-E31), (I-E32), (I-E33), (I-E34), (I-E35), (I-E36), (I-E37), (I-E38), (I-E39 ...40), (I-E41), (I-E42), (I-E43), (I-E44), (I-E45), (I-E4 Each and every embodiment is understood and described as applying to (I-E2), (I-E3), (I-F), (I-G), (I-H), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, as if each and every embodiment were specifically and individually recited, and all such embodiments are understood and described as being capable of being used in any of the pharmaceutical compositions, methods, kits, uses, or other aspects detailed herein.

[0020] In one aspect, provided herein is a pharmaceutical composition comprising: (i) a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition comprising: (i) a compound of formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (ii) one or more pharmaceutically acceptable excipients. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0021] In one aspect, provided herein is a method for modulating SLC6A19 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0022] In one aspect, provided herein is a method of modulating SLC6A19 in a cell, the method comprising exposing a cell to an effective amount of a compound of formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating SLC6A19 in a cell, the method comprising exposing a cell to an effective amount of a pharmaceutical composition comprising an effective amount of (i) a compound of formula (I'), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a compound of formula (I'), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, modulating SLC6A19 comprises inhibiting SLC6A19. In some embodiments, this aspect relates to a compound represented by formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0023] In one aspect, provided herein is a method for inhibiting SLC6A19 in a cell, the method comprising exposing the cell to (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0024] In one aspect, provided herein is a method of inhibiting SLC6A19 in a cell, the method comprising exposing the cell to (i) an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting SLC6A19 in a cell, the method comprising exposing the cell to an effective amount of (i) a compound of Formula (I'), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a compound of Formula (I'), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0025] In one aspect, provided herein is a method of modulating SLC6A19 in a cell of an individual in need thereof, comprising administering to the individual an effective amount of (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, modulating SLC6A19 comprises inhibiting SLC6A19. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0026] In one aspect, provided herein is a method for modulating intracellular SLC6A19 in a cell of an individual in need thereof, the method comprising administering to the individual an effective amount of (i) an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating SLC6A19 in a cell of an individual in need thereof, comprising administering to the individual an effective amount of (i) a compound of formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, modulating SLC6A19 comprises inhibiting SLC6A19. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0027] In one aspect, provided herein is a method of treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the disease, disorder, or condition is responsive to inhibition of SLC6A19. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0028] In one aspect, provided herein is a method of treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of (i) an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of (i) a compound of Formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the disease, disorder, or condition is responsive to inhibition of SLC6A19. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0029] In another variation, provided herein is a method of treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) a compound of Formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, a therapeutically effective amount of the compound or pharmaceutical composition is administered. In some embodiments, the disease, disorder, or condition is responsive to inhibition of SLC6A19. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0030] In one aspect, provided herein is a kit comprising: (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0031] In one aspect, provided herein is a kit comprising: (i) an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit comprising (i) an effective amount of a compound of formula (I'), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of formula (I'), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use thereof in an individual in need of treatment for an SLC6A19-mediated disease, disorder, or condition. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0032] In another variation, provided herein are kits comprising: (i) a compound of Formula (I'), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of Formula (I'), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof. In some embodiments, the kit comprises a therapeutically effective amount of the compound or pharmaceutical composition. In some embodiments, this aspect is achieved by the use of a compound of formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), Any of the compounds (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be utilized.

[0033] In some aspects, the present disclosure relates to compounds of formula (I) or any embodiment or variation thereof, e.g., formula (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D), (I-E), (I-F), (I-G), (I-H), (I- ...

[0023] Methods for preparing a compound of formula I, II-A, II-B, II-C, II-D, II-D, II-D, II-D2, II-E, II-G, or II-H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are provided. In another variation, the present specification refers to a compound of formula (I') or any embodiment or variation thereof, e.g., formula (II), (I'), (I), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), , (I-D1), (I-D2), (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0034] All pharmaceutical compositions, methods, kits, uses, or other aspects described herein with respect to Formula (I) or (I'), or a pharmaceutically acceptable salt of any of the foregoing, are also described and encompassed herein with respect to any one of the other formulas detailed herein, such as Formula (II), as if each and every embodiment were specifically and individually recited. DETAILED DESCRIPTION OF THE INVENTION

[0035] "Individual" refers to a mammal, including humans and non-human mammals. Examples of individuals include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, individual refers to a human.

[0036] As used herein, "about" a parameter or value includes and describes the parameter or value itself. For example, "about X" includes and describes X itself.

[0037] As used herein, an "at risk" individual is an individual who is at risk of developing a disease or condition. An "at risk" individual may or may not have a detectable disease or condition, and may or may not exhibit detectable disease prior to the treatment methods described herein. "At risk" refers to an individual having one or more so-called risk factors, which are measurable parameters that correlate with the development of a disease or condition and are known in the art. Individuals who have one or more of these risk factors are more likely to develop a disease or condition than individuals who do not have these risk factor(s).

[0038] "Treatment" or "treating" is an approach to obtaining beneficial or desired results, including clinical results. Beneficial or desired results can include one or more of the following: reducing one or more symptoms caused by a disease or condition; attenuating the severity of a disease or condition; slowing or halting the onset of one or more symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or delaying the worsening or progression of a disease or condition); and alleviating the disease, such as by causing regression of clinical symptoms (e.g., ameliorating a disease state, enhancing the effectiveness of another medication, slowing the progression of a disease, improving quality of life, and / or prolonging survival).

[0039] As used herein, "delaying" the onset of a disease or condition means to postpone, prevent, slow, retard, stabilize, and / or postpone the onset of the disease or condition. This delay can be of varying lengths of time, depending on the disease being treated and / or the medical history of the individual. As will be apparent to one of skill in the art, a sufficient or significant delay can, in fact, encompass prevention, in that the individual does not develop the disease or condition.

[0040] As used herein, the term "therapeutically effective amount" or "effective amount" refers to the amount of the compound of the present disclosure or its pharmaceutical salt that is sufficient to be effective when administered to an individual.As understood in the art, an effective amount can be in one or more dosages, for example, a single dosage or multiple dosages may be required to achieve a desired therapeutic endpoint.An effective amount can be considered in relation to the administration of one or more therapeutic agents, and when a desired or effective result can be achieved or achieved in conjunction with one or more other agents, a single agent can be considered to be given in an effective amount.

[0041] As used herein, "unit dosage form" refers to physically discrete units suitable as unit dosages, each containing a predetermined amount of active ingredient or compound (which may be in a pharmaceutically acceptable carrier).

[0042] As used herein, "pharmaceutically acceptable" means a substance that is not biologically or otherwise undesirable, e.g., the substance can be incorporated into a pharmaceutical composition to be administered to an individual without causing significant undesired biological effects.

[0043] The term "alkyl," as used herein, refers to an unbranched or branched saturated monovalent hydrocarbon chain. As used herein, alkyl refers to an alkyl group having 1 to 20 carbons (i.e., C 1~20 alkyl), 1 to 16 carbons (i.e., C 1~16 alkyl), 1 to 12 carbons (i.e., C1~12 alkyl), 1 to 10 carbons (i.e., C 1~10 alkyl), 1 to 8 carbons (i.e., C 1~8 alkyl), 1 to 6 carbons (i.e., C 1~6 alkyl), 1 to 4 carbons (i.e., C 1~4 alkyl), or 1 to 3 carbons (i.e., C 1~3 alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neo-pentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbon atoms is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms are encompassed. For example, "butyl" includes n-butyl, sec-butyl, isobutyl, and tert-butyl; "propyl" includes n-propyl and isopropyl. Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkyl" group, may be referred to as an "alkylene."

[0044] The term "alkenyl," as used herein, refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon double bond. As used herein, alkenyl refers to a hydrocarbon chain having 2 to 20 carbons (i.e., C 2~20 alkenyl), 2 to 16 carbons (i.e., C 2~16 alkenyl), 2 to 12 carbons (i.e., C 2~12 alkenyl), 2 to 10 carbons (i.e., C 2~10 alkenyl), 2 to 8 carbons (i.e., C 2~8 alkenyl), 2 to 6 carbons (i.e., C 2~6 alkenyl), 2 to 4 carbons (i.e., C 2~4 alkenyl), or 2-3 carbons (i.e., C 2~3Alkenyl groups include, but are not limited to, ethenyl, prop-1-enyl, prop-2-enyl-1,2-butadienyl, and 1,3-butadienyl. When an alkenyl residue having a specific number of carbon atoms is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms are encompassed. For example, "propenyl" includes prop-1-enyl and prop-2-enyl. Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkenyl" group, may be referred to as "alkenylene."

[0045] The term "alkynyl," as used herein, refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon triple bond. As used herein, alkynyl refers to a hydrocarbon chain having 2 to 20 carbons (i.e., C 2~20 alkynyl), 2 to 16 carbons (i.e., C 2~16 alkynyl), 2 to 12 carbons (i.e., C 2~12 alkynyl), 2 to 10 carbons (i.e., C 2~10 alkynyl), 2 to 8 carbons (i.e., C 2~8 alkynyl), 2 to 6 carbons (i.e., C 2~6 alkynyl), 2-4 carbons (i.e., C 2~4 alkynyl), or 2-3 carbons (i.e., C 2~3 alkynyl). Examples of alkynyl include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, and but-3-ynyl. When an alkynyl residue having a specific number of carbon atoms is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms are encompassed. For example, "propynyl" includes prop-1-ynyl and prop-2-ynyl. Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkynyl" group, may be referred to as an "alkynylene."

[0046] The term "alkoxy," as used herein, refers to an -O-alkyl moiety. For example, example alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0047] The term "thioalkyl," as used herein, refers to an --S-alkyl group.

[0048] The term "aryl," as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term "aryl" encompasses monocyclic and polycyclic fused ring moieties. As used herein, aryl refers to, for example, a ring having 6 to 20 ring carbon atoms (i.e., C 6~20 aryl), 6 to 16 ring carbon atoms (i.e., C 6~16 aryl), 6 to 12 ring carbon atoms (i.e., C 6~12 aryl), or 6 to 10 ring carbon atoms (i.e., C 6~10 Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.

[0049] The term "cycloalkyl," as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term "cycloalkyl" encompasses monocyclic and polycyclic ring moieties, which may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, where the ring moiety contains at least one ring double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety containing at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, cycloalkyl refers to a group having, for example, 3 to 20 ring carbon atoms (i.e., C 3~20 cycloalkyl), 3 to 16 ring carbon atoms (i.e., C 3~16 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3~12cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3~10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3~8 cycloalkyl), 3 to 6 ring carbon atoms (i.e., C 3~6 cycloalkyl), or 3 to 5 ring carbon atoms (i.e., C 3~5 Cycloalkyl includes rings containing cycloalkyl groups. Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Cycloalkyl also includes spirocycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl.

[0050] The term "halo," as used herein, refers to an atom occupying group VIIA of the periodic table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo). Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "C1-C4 haloalkyl" is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, and the like.

[0051] The term "heteroaryl," as used herein, refers to an aromatic (fully unsaturated) ring moiety containing one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heteroaryl" includes both monocyclic and polycyclic fused ring moieties. As used herein, heteroaryl includes, for example, 5 to 20 ring atoms (i.e., 5-20-membered heteroaryl), 5 to 16 ring atoms (i.e., 5-16-membered heteroaryl), 5 to 12 ring atoms (i.e., 5-12-membered heteroaryl), 5 to 10 ring atoms (i.e., 5-10-membered heteroaryl), 5 to 8 ring atoms (i.e., 5-8-membered heteroaryl), or 5 to 6 ring atoms (i.e., 5-6-membered heteroaryl). Any monocyclic or polycyclic aromatic ring moiety containing one or more ring heteroatoms is considered heteroaryl, regardless of the point of attachment to the remainder of the molecule (i.e., the heteroaryl moiety can be attached to the remainder of the molecule through any ring carbon or any ring heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, and isoquinolinyl. Examples of aryl include, but are not limited to, aryl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, and triazinyl.Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, where the heteroaryl may be attached via either ring of the fused system.

[0052] The term "heterocyclyl," as used herein, refers to a saturated or partially unsaturated cyclic moiety containing one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heterocyclyl" includes both monocyclic and polycyclic ring moieties, which may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic ring moiety containing at least one ring heteroatom is considered heterocyclyl, regardless of the point of attachment to the rest of the molecule (i.e., the heterocyclyl moiety can be attached to the rest of the molecule through any ring carbon or any ring heteroatom of the heterocyclyl moiety). Furthermore, the term heterocyclyl is intended to encompass any polycyclic ring moiety containing at least one ring heteroatom, where the polycyclic ring moiety contains at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, heterocyclyl includes, for example, 3 to 20 ring atoms (i.e., 3-20-membered heterocyclyl), 3 to 16 ring atoms (i.e., 3-16-membered heterocyclyl), 3 to 12 ring atoms (i.e., 3-12-membered heterocyclyl), 3 to 10 ring atoms (i.e., 3-10-membered heterocyclyl), 3 to 8 ring atoms (i.e., 3-8-membered heterocyclyl), 3 to 6 ring atoms (i.e., 3-6-membered heterocyclyl), 3 to 5 ring atoms (i.e., 3-5-membered heterocyclyl), 5 to 8 ring atoms (i.e., 5-8-membered heterocyclyl), or 5 to 6 ring atoms (i.e., 5-6-membered heterocyclyl).Examples of heterocyclyl groups include, for example, azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoquinolyl, and the like. These include isoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiroheterocyclyl rings include, but are not limited to, bicyclic and tricyclic ring systems such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl may be attached via either ring of the fused system.

[0053] As used herein, the term "oxo" refers to a =O moiety.

[0054] As used herein, the terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and the description includes both cases where the event or circumstance occurs. Thus, the term "optionally substituted" implies that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the specified atom, moiety, or group may or may not be replaced by a non-hydrogen atom, moiety, or group. By way of example, and not limitation, the phrase "methyl optionally substituted with one or more chloro" encompasses -CH, -CHCl, -CHCl, and -CCl moieties.

[0055] Aspects and embodiments described herein as "comprising" are understood to include "consisting of" and "consisting essentially of" embodiments.

[0056] As used herein, the term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" include, for example, salts with inorganic acids and salts with organic acids. Also, when a compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, when the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from base compounds. See, for example, "Handbook of Pharmaceutical Salts Properties, Selection, and Use," International Union of Pure and Applied Chemistry, John Wiley & Sons (2008) (incorporated herein by reference). Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Salts derived from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, trifluoroacetic acid, etc. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium salts, potassium salts, lithium salts, aluminum salts, ammonium salts, calcium salts, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary amines, secondary amines, and tertiary amines.Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(iso-propyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0057] Isotopically labeled forms of the compounds described herein can be prepared.Isotopically labeled compounds have the structure described herein, except that one or more atoms are replaced by atoms with a selected atomic mass or mass number.Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, for example, 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 In some embodiments, compounds of formula (I') or (I) are provided in which one or more hydrogens are replaced with deuterium or tritium.

[0058] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and the nature of the equilibrium between the tautomers, it will be understood by those skilled in the art that the compounds of the present disclosure include both amide acid tautomers and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers.

[0059] Also provided herein is the prodrug of the compound disclosed herein, or its pharmaceutically acceptable salt.Prodrug is a compound that can be administered to an individual and release the compound disclosed herein as a parent drug compound in vivo.It is understood that prodrug can be prepared by modifying the functional group on the parent drug compound, so that the modification is cleaved in vitro or in vivo to release the parent drug compound.See, for example, Rautio, J., Kumpulainen, H., Heimbach, T. et al.Prodrugs: design and clinical applications.Nat Rev Drug Discov 7,255-270(2008) (incorporated herein by reference).

[0060] The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may contain asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined in terms of absolute stereochemistry as (R)- or (S)- (or, in the case of amino acids, as (D)- or (L)-). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, such as chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC) and chiral supercritical fluid chromatography (SFC). Where the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the disclosure is intended to include both E and Z geometric isomers. Similarly, cis- and trans- are used in their conventional sense to describe their relative spatial relationships.

[0061] "Stereoisomers" refer to compounds composed of the same atoms bonded by the same bonds but with different, non-interchangeable three-dimensional structures. The present disclosure contemplates various stereoisomers, or mixtures thereof, including "enantiomers," which refer to two stereoisomers whose structures are non-superimposable mirror images of each other. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other.

[0062] Where enantiomeric and / or diastereomeric forms of a given structure exist, a planar bond indicates that all stereoisomeric forms of the shown structure may be present. For example, [ka]

[0063] Where enantiomeric and / or diastereomeric forms of a given structure exist having two stereocenters, the presence of a wedge bond and / or dashed bond and two "&1" symbols indicates that the composition is made up of a pair of enantiomers with known relative stereochemistry. For example, [ka]

[0064] compound In one aspect, provided herein is a compound of formula (II): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, -C(O)C 1~6 Alkyl, C 3~10 Cycloalkyl, -N(R 4 )2, 5- to 20-membered heteroaryl, -C 1~6 alkyl (5- to 20-membered heteroaryl), or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a optionally replaced by R 3is a 6- to 10-membered heteroaryl, the 6- to 10-membered heteroaryl is unsubstituted; Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, -C 1~6 Alkyl (5-20 membered heteroaryl), or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Thioalkyl, C 3~10 Cycloalkyl, C 1~6 haloalkyl, or 5- to 20-membered heteroaryl, wherein R 5 and R 7 C 1~6 Alkyl, C 1~6 Alkoxy, or C 3~10 each cycloalkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 1~6 Alkoxy, C 3~10 Cycloalkyl, -OC 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, 5- to 20-membered heteroaryl, or -(R x )-5 to 20-membered heteroaryl), where each R 8 is one or more R a is optionally replaced by R x is -NH- or -O-, R 10is, independently for each occurrence, H or D, R 11a and R 11b is independently H or C at each occurrence 1~6 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a Or R 12b Together with one of the 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, Each R a are independently D, -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, -C(O)NH2, -C(O)NH(C 1~6 alkyl), -C(O)N(C 1~6 alkyl) 2, 4- to 10-membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl, C 3~10 Cycloalkyl, or -OC3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b are independently D, -OH, halo, C 1~6 Alkyl, or C 1~6 It is an alkoxy.

[0065] In one aspect, provided herein is a compound of formula (I'): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a Or R 12b Together with one of the 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the3~10 forming a cycloalkyl, Each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, -C(O)NH2, -C(O)NH(C 1~6 alkyl), -C(O)N(C 1~6 alkyl) 2, 4- to 10-membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b independently for each occurrence: D, -OH, halo, C 1~6 Alkyl, or C 1~6 It is an alkoxy.

[0066] In one aspect, provided herein is a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, -O-, or -S-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R4)2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 alkyl or R 12a Or R 12bC together with one of 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, and Each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 It is cycloalkyl.

[0067] Any embodiment provided herein of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, is also an embodiment of a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. Any embodiment provided herein of a compound of formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, is also a compound of formula (II), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), (I-D3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0068] Any embodiment provided herein of a compound of Formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, applies equally, where applicable, to any other formula detailed herein, as if each and every embodiment were specifically and individually recited. Thus, each embodiment provided herein of a compound of Formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, e.g., m, n, R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R11a , R 11b It is understood and described that embodiments relating to m, n, R, and X apply to Formula (II) as if each and every embodiment were specifically and individually recited. All such embodiments are also understood and described as being capable of being used in any of the pharmaceutical compositions, methods, kits, uses, or other aspects detailed herein. It is also understood and described that each embodiment provided herein of a compound of Formula (I) or (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, e.g., m, n, R, 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 11b , and embodiments relating to X include those of formula (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), (I-D 3), (IE), (I-E1), (I-E2), (I-E3), (IF), (IG), (IH), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0069] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound may possess any one or more of the following structural features: (a) m is 1 and R 1 -NH- or -N(C 1~6 alkyl), (b) X is -O-, n is an integer of 0 to 2, and R 8But -C(O)N(R 4 )2, C 1~6 Alkoxy, C 3~10 Cycloalkyl, -OC 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a , optionally replaced by (c) X is -N(H)- or -N(C 1~6 alkyl)-, n is 1, and R 8 But C 6~20 aryl, or 5- to 20-membered heteroaryl, where each R 8 is one or more R a , optionally replaced by (d) X is -C(R 12a )(R 12b )-, n is 0 or 1, and R 8 But C 6~20 aryl, 5- to 20-membered heteroaryl, or -(R x )-5 to 20-membered heteroaryl), where each R 8 is one or more R a and optionally substituted with R x is —NH— or —O—; (e) X is -S-, n is 1, and R 8 is a 5- to 20-membered heteroaryl; (f)R 3 But C 1~6 Alkyl, C 1~6 Alkoxy, -C(O)C 1~6 Alkyl, C 3~10 Cycloalkyl, -N(R 4 )2, 5- to 20-membered heteroaryl, -C 1~6 alkyl (5- to 20-membered heteroaryl), or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by R 3 is a 6- to 10-membered heteroaryl, the 6- to 10-membered heteroaryl is unsubstituted; (g)R3 But C 1~6 Alkyl, C 3~10 cycloalkyl, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a , optionally replaced by (h)R 3 But C 3~10 cycloalkyl, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and / or (i)R 3 but one or more R a C optionally replaced with 3~10 It is cycloalkyl. In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound comprises (a). In some embodiments, the compound comprises (a), (b), and (f). In some embodiments, the compound comprises (a), (c), and (g). In some embodiments, the compound comprises (a), (d), and (h). In some embodiments, the compound comprises (a), (e), and (i).

[0070] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 alkyl or R 12a Or R 12b C together with one of 3~10 forming a cycloalkyl, R 12a and R 12bare each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, and Each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0071] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, R 2 is H, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 10-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~6 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a Or R 12b Together with one of the 3~10 forming a cycloalkyl, R12a and R 12b are each independently H or C 1~6 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 forming a cycloalkyl, Each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer of 1 to 2, n is an integer from 0 to 2, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, R 2is H, R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 6-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~3 alkyl or R 12a Or R12b C together with one of 3~6 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~3 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 forming a cycloalkyl, and Each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0072] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer of 1 to 2, n is an integer from 0 to 2, X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, R 1 is -NH-, R 2 is H, R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a is optionally replaced by Each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 is cycloalkyl, or Both R 4 together with the N atoms to which they are attached, form one or more R a forming a 4- to 6-membered heterocyclyl optionally substituted by R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo; R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H, R 11a and R 11b is independently H or C at each occurrence 1~3 is alkyl, or R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12aOr R 12b Together with one of the 3~10 forming a cycloalkyl, R 12a and R 12b are each independently H or C 1~3 is alkyl, or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 forming a cycloalkyl, Each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~10 Cycloalkyl can be one or more R b is optionally replaced by, and Each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 It is an alkoxy.

[0073] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4; n is an integer from 0 to 4; X is —N(H)—; and R 1 is -NH- and R 2 is H and R 3is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is independently H or C at each occurrence 1~6 alkyl or R 12a Or R 12b C together with one of 3~10 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 alkyl or R12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is an integer from 0 to 2, X is -N(H)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is independently H or C at each occurrence 1~3 alkyl or R 12a Or R 12b C together with one of 3~6 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0074] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, and X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12bOne of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl or C 1~6 In some embodiments, m is an integer from 1 to 2, n is 1, and X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4-6 heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R12b One of them is H or C 1~3 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~3 Alkyl, -C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 It is an alkoxy.

[0075] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, and X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is 1, and X is -O-, -S-, -C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12 b's are independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0076] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, X is -O-, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2-, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl or C 1~6 In some embodiments, m is an integer from 1 to 2, n is 1, X is -O-, and R 1 is -NH- and R 2 is H and R 3 is C1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4-6 heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~3 Alkyl, -C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 It is an alkoxy.

[0077] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, X is —O—, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R aand R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is 1, X is -O-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11bTogether with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0078] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, X is -S-, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is 1, X is -S-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0079] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, and X is —C(R 12a )(R 12b )- and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is optionally substituted with one or more Ra, and R 10 is H and R 11a及 BiR 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is 1, and X is -C(R 12a )(R 12b )- and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R aand R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6In some variations, this embodiment also includes, for example, cycloalkyl, of formula (II), (I'), (IA), (I-A1), (I-A2), (I-A3), (I-A4), (I-A5), (I-A6), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (IC), (I-C1), (I-C2), (I-C3), (I-C4), (I-C5), (ID), (I-D1), (I-D2), (I-D3), (IE), (I- E1), (I-E2), (I-E3), (I-F), (I-G), (I-H), (II-A), (II-B), (II-C), (II-D), (II-D1), (II-D2), (II-E), (II-G), (II-H), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0080] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is an integer from 0 to 4, and X is -N(H)- or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2, or 4- to 10-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is, independently for each occurrence, H, and R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is 1, and X is -N(H)- or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R11b is, independently for each occurrence, H, and R 12a及 BiR 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each Ra independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0081] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, and X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 1 is -NH- and R 2 is H and R 3 is one or more R a C optionally replaced with 3~10 is cycloalkyl, and R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R 10is H and R 11a and R 11b is independently H or C at each occurrence 1~6 Alkyl or R 12a Or R 12b C together with one of 3~10 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~6 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R1 2b The other side is R 11a Or R 11b Together with one of the 3~10 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, m is an integer from 1 to 2, n is an integer from 0 to 2, X is -O-, and R 1 is -NH- and R 2 is H and R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R 10 is H and R 11a and R 11b is independently H or C at each occurrence 1~3 alkyl or R 12a Or R 12b C together with one of 3~6 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~6 alkyl, and R 12a and R 12b The other side is R 11a Or R 11b Together with one of the 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0082] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R3 is C 1~6 In some embodiments, R 3 is C 1~6 alkyl, and R 5 and R 7 are each independently H, halo, or C 1~6 alkyl, and R 6 and R 9 are each independently H or halo. [ka] The part represented by [ka] is selected from the group consisting of:

[0083] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0084] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0085] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is one or more R a C optionally replaced with 1~6 In some embodiments, R 3 is one or more R a C is replaced by 1~6 alkyl, and R 5 and R 7 are each H or halo, and R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] [ka] is selected from the group consisting of:

[0086] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] is selected from the group consisting of:

[0087] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is one or more R a C optionally replaced with 3~6 In some embodiments, R 3 is one or more R a C is replaced by 3~6 is cycloalkyl, and R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Thioalkyl, C 3~10 Cycloalkyl, C 1~6 haloalkyl, or 5- to 20-membered heteroaryl, where R 5 and R 7 C 1~6 Alkyl, C 1~6 Alkoxy, or C 3~10 Each cycloalkyl is independently optionally substituted with one or more halo or CN; R6 and R 9 are each independently H or halo. [ka] The part represented by [ka] [ka] [ka] is selected from the group consisting of:

[0088] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, [ka] The part represented by [ka] In some embodiments, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0089] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, [ka] The part represented by [ka] In some embodiments, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0090] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] [ka] is selected from the group consisting of:

[0091] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, R 5 and R 7 are each independently H or halo, and R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] In some embodiments, R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Alkyl, C 1~6 Alkoxy, or C 3~10 Each cycloalkyl is independently optionally substituted with one or more halo; R 6 and R 9 are each independently H or halo. [ka] The part represented by [ka] [ka] [ka] is selected from the group consisting of:

[0092] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0093] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0094] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is one or more R a In some embodiments, R is a 4- to 10-membered heterocyclyl optionally substituted with 3 is one or more R a and R is a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently halo; R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] [ka] is selected from the group consisting of:

[0095] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] is selected from the group consisting of:

[0096] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is one or more R a In some embodiments, R is a 5- to 20-membered heteroaryl optionally substituted with 3 is one or more R a and R is a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently halo; R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0097] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is -C(O)C 1~6 In some embodiments, R 3 is -C(O)C 1~6 alkyl, and R 5 and R 7 are each independently halo; R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] is.

[0098] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is C 1~6 In some embodiments, R 3 is C 1~6 is alkoxy, and R 5 and R 7 are each independently halo; R 6 and R 9 are each H. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0099] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is C 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0100] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is a 5- to 20-membered heteroaryl. In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0101] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0102] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is one or more R a C optionally replaced with 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0103] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] wherein n is an integer of 0 to 2, and R 8 is one or more R a C optionally replaced with 3~10 In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0104] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, this embodiment also applies to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0105] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 3 is C 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0106] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is 3-10 membered heterocyclyl. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0107] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, this embodiment also applies to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0108] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] wherein n is 1 or 2, and R 8 is one or more R a In some embodiments, [ka] The part represented by [ka] [ka] is selected from the group consisting of:

[0109] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some embodiments, the compound is selected from the group consisting of: [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0110] In some embodiments of the compound of Formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] is selected from the group consisting of:

[0111] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where n is 2 and R 8 is C 1~6 Alkoxy or -OC 3~10 cycloalkyl, and each R 8 is one or more R a In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0112] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is -(R x )-5 to 20-membered heteroaryl), and R x is —NH— or —O—. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0113] In some embodiments of the compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] wherein one or more R a 5-20 membered heteroaryl optionally substituted with R 11a and R 11b are each independently H or C 1~6 alkyl, and R 12a and R 12b are each independently H or C 1~6 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0114] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is C 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0115] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is one or more R a In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0116] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is one or more R a In some embodiments, R is a 5- to 20-membered heteroaryl optionally substituted with 8 is one or more R a and R is a 5- to 20-membered heteroaryl optionally substituted with 5 and R 7 are each independently H or halo, and R 6 and R 9 are each H or halo. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0117] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is C 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0118] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is one or more R a C optionally replaced with 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0119] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is one or more R a In some embodiments, [ka] The part represented by [ka] [ka] In some embodiments of the compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] [ka] [ka] [ka] [ka] Further, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0120] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] wherein n is 0 or 1, and R 8 is one or more R a C optionally replaced with 3~10 In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0121] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0122] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is C 3~10 In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0123] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, this embodiment also applies to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0124] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, this embodiment also applies to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0125] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where n is 2 and R 8 is C 1~6 Alkoxy or -OC 3~10 cycloalkyl, and each R 8is one or more R a In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0126] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is a 5- to 20-membered heteroaryl. In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0127] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] wherein n is 0 or 1, and R 8 is a 5-20 membered heteroaryl. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0128] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, this embodiment also applies to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0129] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is -(Rx )-5 to 20-membered heteroaryl), and R x is —NH— or —O—. In some embodiments, [ka] The part represented by [ka] is selected from the group consisting of:

[0130] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is C 6~20 In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0131] In some embodiments of a compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] where R 8 is a 5- to 20-membered heteroaryl. In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] The part represented by [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0132] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -NH-, -O-, or -S-. In some embodiments, R 1 is —O—. In some embodiments, R 1 is -S-. In some embodiments, R 1 is -NH-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0133] In one aspect, provided herein are compounds of formula (I), such as compounds of formula (IA): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0134] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4. In some embodiments, m is an integer from 1 to 2. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0135] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0 to 4. In some embodiments, n is an integer from 0 to 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0136] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, and n is an integer from 0 to 4. In some embodiments, m is an integer from 1 to 2, and n is an integer from 0 to 2. In some embodiments, m is 1 and n is 0. In some embodiments, m is 1 and n is 1. In some embodiments, m is 1 and n is 2. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0137] In some embodiments of the compounds of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 In some embodiments, X is —O—, —S—, —C(R alkyl)-. 12a )(R 12b )-, -N(H)-, or -N(C 1~3In some embodiments, X is -O-. In some embodiments, X is -S-. In some embodiments, X is -C(R alkyl). 12a )(R 12b )-. In some embodiments, X is -N(H)-. In some embodiments, X is -N(C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0138] In some embodiments of the compounds of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —CH—, —CH(C 1~6 alkyl)-, or -C(C 1~6 In some embodiments, X is -CH-, -CH(C 1~3 alkyl)-, or -C(C 1~3 In some embodiments, X is -CH-. In some embodiments, X is -CH(CH)-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0139] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —N(R 12)-. In some embodiments, X is -NH-. In some embodiments, X is -NMe-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0140] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~10 Cycloalkyl, -N(R 4 ) 2-, or 4-, 5-, or 10-membered heterocyclyl, and each R 3 is one or more R a In some embodiments, R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a In some embodiments, R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0141] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 1~6 In some embodiments, R 3 is C 1~3 In some embodiments, R 3 is methyl, ethyl, or isopropyl. In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl. In some embodiments, R 3 is isopropyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0142] In some embodiments of a compound of Formula (I') or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 1~6 alkyl, and R a -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where Ra C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments, R 3 is one or more R a C optionally replaced with 1~3 alkyl, and R a -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is one or more R a C optionally replaced with 1~3 alkyl, and R a -OH, halo, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R bindependently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0143] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 1~6 alkyl, and R a D, -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, -C(O)NH2, -C(O)NH(C 1~6 alkyl), -C(O)N(C 1~6 alkyl)2, 4-10 membered heterocyclyl, 5-20 membered heteroaryl, C 3~10 Cycloalkyl, or -OC 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 Cycloalkyl can be one or more R b and each R b are independently D, -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments, R 3 is one or more R a C optionally replaced with 1~3 alkyl, and R aD, -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3 alkyl)2, -C(O)NH2, -C(O)NH(C 1~3 alkyl), -C(O)N(C 1~3 alkyl)2, 4-6 membered heterocyclyl, 5-10 membered heteroaryl, C 3~6 Cycloalkyl, or -OC 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4-10 membered heterocyclyl, C 3~10 Cycloalkyl, or -OC 3~10 Cycloalkyl can be one or more R b and each R b are independently D, -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is one or more R a C optionally replaced with 1~3 alkyl, and R a -OH, halo, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0144] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 1~6 In some embodiments, R 3 is C 1~3 In some embodiments, R 3 is methoxy, ethoxy, or isopropoxy. In some embodiments, R 3 is methoxy. In some embodiments, R 3 is ethoxy. In some embodiments, R 3 is isopropoxy.

[0145] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a -C(O)C optionally substituted with 1~6 In some embodiments, R 3 is -C(O)C 1~3 In some embodiments, R 3 is —C(O)methyl or —C(O)methylethyl. In some embodiments, R 3 is —C(O)methyl.

[0146] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 3~10 is cycloalkyl, and R a -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10In some embodiments, R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a is C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is one or more C 1~3 Alkyl or C 1~3 C optionally substituted with haloalkyl 3~6 In some embodiments, R 3 is one or more C 1~3 Alkyl or C 1~3 In some embodiments, R is cyclopropyl optionally substituted with haloalkyl. 3 teeth, [ka] In some embodiments, R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a is halo. In some embodiments, R 3 is C optionally substituted with one or more Br, Cl, I, or F 3~6 In some embodiments, R 3 is cyclopropyl optionally substituted with one or more of Br, Cl, I, or F. In some embodiments, R 3 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0147] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a C optionally replaced with 3~10 is cycloalkyl, and R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments, R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a is independently for each occurrence -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3alkyl), -N(C 1~3 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 haloalkyl, and R a C 1~3 Alkyl is one or more R b and each R b is, independently at each occurrence, -OH or C 1~3 In some embodiments, R 3 is one or more -OH, halo, C 1~3 Alkyl, C 1~3 C optionally substituted with haloalkyl 3~6 cycloalkyl, where C 1~3 Alkyl is one or more -OH or C 1~3 In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0148] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more -OH, halo, C 1~3Alkyl, or C 1~3 C optionally substituted with haloalkyl 3~6 cycloalkyl, where C 1~3 Alkyl is one or more of D, -OH, or C 1~3 In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0149] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is -N(R 4 )2, and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 3 is -N(R 4 )2, and each R 4 are independently H, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, R 3 is -N(R 4 )2, and each R 4 are independently H or C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0150] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3is one or more R a and R is a 4- to 10-membered heterocyclyl optionally substituted with a -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a Ha, Halo, C 1~3 Alkyl, or C 1~3 In some embodiments, one or more halo, C 1~3 Alkyl, or C 1~3 4-6 membered heterocyclyl optionally substituted with haloalkyl. In some embodiments, R 3 is azetidine, pyrrolidine, or piperidine, and each R 3 is one or more halo, C 1~3 Alkyl, or C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0151] In some embodiments of a compound of Formula (I') or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a and R is a 4- to 10-membered heterocyclyl optionally substituted with ais independently for each occurrence -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a is independently for each occurrence -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R band each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 haloalkyl, and R a C 1~3 Alkyl is one or more R b and each R b is, independently at each occurrence, -OH or C 1~3 In some embodiments, R 3 is one or more R a and R is a 4- to 6-membered heterocyclyl optionally substituted with a is, independently at each occurrence, -CN, halo, or C 1~3 alkyl, where R a C 1~3 Alkyl is one or more R b and each R b is OH. In some embodiments, R 3 is one or more -CN, halo, or C 1~3 4-6 membered heterocyclyl optionally substituted with alkyl, where R a C 1~3 The alkyl is optionally substituted with one or more OH. In some embodiments, R 3 teeth, [ka] In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0152] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is -N(R 4 )2, and both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with a -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 3 is -N( R4 )2, and both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 3 is -N(R 4 )2, and both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with a Ha, Halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 3 is -N(R 4 )2, and both R 4 together with the N atoms to which they are attached, form one or more halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R forms a 4-6 membered heterocyclyl optionally substituted with haloalkyl. 3 teeth, [ka] In some embodiments, R 3 teeth, [ka] In some embodiments, R 3 teeth, [ka] In some embodiments, R 3 teeth, [ka] In some embodiments, R 3 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0153] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is -N(R 4 )2, and both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with a OH, CN, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, or C 3~10 is cycloalkyl, and R a C 1~6 The alkyl is optionally substituted with one or more OH. In some embodiments, R 3 teeth, [ka] is selected from the group consisting of:

[0154] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a 5-20 membered heteroaryl optionally substituted with 3 is a 6- to 10-membered heteroaryl, and the 6- to 10-membered heteroaryl is unsubstituted. 3 is one or more R a In some embodiments, R is a 5-membered heteroaryl optionally substituted with 3 is a 5-membered heteroaryl. In some embodiments, R 3 teeth, [ka] is.

[0155] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 is one or more R a -C is optionally replaced with 1~6 alkyl(5-20 membered heteroaryl). In some embodiments, R 3 is one or more R a -C is optionally replaced with 1~6 alkyl(5-membered heteroaryl). In some embodiments, R 3 -C 1~6 alkyl(5-membered heteroaryl). In some embodiments, R 3 teeth, [ka] is.

[0156] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Thioalkyl, C 3~10 Cycloalkyl, C 1~6 haloalkyl, or 5- to 20-membered heteroaryl, where R 5 and R 7 C 1~6 Alkyl, C 1~6 Alkoxy, or C 3~10 Each cycloalkyl is independently optionally substituted with one or more halo or CN. In some embodiments, R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Thioalkyl, C 3~6 Cycloalkyl, C 1~3 haloalkyl, or 5-10 membered heteroaryl, where R 5 and R 7 C 1~3 Alkyl, C 1~3 Alkoxy, or C 3~6 Each cycloalkyl is independently optionally substituted with one or more halo or CN.

[0157] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN. In some embodiments, R5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN. In some embodiments, R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, or C 1~3 In some embodiments, R 5 and R 7 are each independently H. In some embodiments, R 5 and R 7 One of the groups is H and the other is R 5 and R 7 The other one is independent, halo, C 1~3 Alkyl, or C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0158] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 9 are each independently H or halo. In some embodiments, R 6 and R 9 are each independently H, F, or Cl. In some embodiments, R 6 and R 9 are each independently H. In some embodiments, R 6 and R 9 are each independently halo. In some embodiments, R6 and R 9 are each independently F or Cl. In some embodiments, R 6 and R 9 One of them is H and R 6 and R 9 and the other is halo. In some embodiments, R 6 and R 9 One of them is H and R 6 and R 9 is F or Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0159] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is -C(O)N(R 4 )2, C 3~10 Cycloalkyl, C 6~20 aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, wherein each R 8 is one or more R a is optionally replaced by R a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more R a is optionally replaced by R a OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C3~6 In some embodiments, R 8 is -C(O)N(R 4 )2, C 3~6 Cycloalkyl, C 6~12 aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, where each R 8 is one or more OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0160] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is -C(O)N(R 4 )2. In some embodiments, R 8 is -C(O)N(R 4 )2, and each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is -C(O)N(R 4 )2, and each R 4 are independently H or C 1~6 In some embodiments, R 8is —C(O)NH, C(O)NHMe, or C(O)NMe. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I′) or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0161] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is one or more R a C optionally replaced with 1~6 In some embodiments, R 8 is one or more R a C optionally replaced with 1~6 is alkoxy, and R a is halo. In some embodiments, R 8 is C 1~3 In some embodiments, R 8 is one or more R a C optionally replaced with 1~3 is alkoxy, and R a is halo. In some embodiments, R 8 teeth, [ka] is selected from the group consisting of:

[0162] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is C 3~10 In some embodiments, R 8 is one or more R a C optionally replaced with 3~10 is cycloalkyl, and R a OH, halo, C 1~6 Alkyl, C1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is C 3~6 In some embodiments, R 8 is one or more R a C optionally replaced with 3~6 is cycloalkyl, and R a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0163] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is C 3~10 In some embodiments, R 8 is one or more R a C optionally replaced with 3~10 Cycloalkyl, R a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, or C 3~10 In some embodiments, R 8 is C 3~6 In some embodiments, R 8 is one or more R a C optionally replaced with 3~6 Cycloalkyl, Ra OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~3 Alkoxy, or C 3~10 In some embodiments, R 8 teeth, [ka] is selected from the group consisting of:

[0164] In some embodiments of the compound of Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 -OC 3~10 In some embodiments, R 8 is one or more R a -OC optionally replaced by 3~10 In some embodiments, R 8 -OC 3~6 In some embodiments, R 8 teeth, [ka] is selected from the group consisting of:

[0165] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is C 6~12 In some embodiments, R 8 is one or more R a C optionally replaced with 6~12 aryl, and R a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is C optionally substituted with one or more -OH 6~12In some embodiments, R 8 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0166] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is a 3- to 10-membered heterocyclyl. In some embodiments, R 8 is one or more R a and R is a 3- to 10-membered heterocyclyl optionally substituted with a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is a 3- to 6-membered heterocyclyl. In some embodiments, R 8 is one or more R a and R is a 3- to 6-membered heterocyclyl optionally substituted with a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments, R 8 teeth, [ka] is selected from the group consisting of:

[0167] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 is a 5- to 20-membered heteroaryl. In some embodiments, R 8 is one or more R a and R is a 5- to 20-membered heteroaryl optionally substituted with a OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R 8 is one or more halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R is a 5-10 membered heteroaryl optionally substituted with cycloalkyl. 8 teeth, [ka] [ka] In some embodiments, R 8 teeth, [ka] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0168] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 11a and R 11b are each, independently for each occurrence, H or C 1~6 In some embodiments, R 11a and R 11b are each, independently for each occurrence, H or C 1~3 In some embodiments, R 11a and R 11b is, each independently at each occurrence, H. In some embodiments, R 11a and R 11b One of them is H and R 11a and R 11b The other is C 1~3 In some embodiments, R 11a and R 11b One of them is H and R 11a and R 11b The other is methyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0169] In some embodiments of a compound of Formula (I) or (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 and R 11a and R 11b One of them is H or C1~6 alkyl, and R 11a and R 11b The other side is R 12a or R 12b Together with one of the 3~10 In some embodiments, n is 1 and R 11a and R 11b One of them is H or C 1~3 alkyl, and R 11a and R 11b The other side is R 12a or R 12b Together with one of the 3~6 In some embodiments, n is 1 and R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a or R 12b together with one of n and R 11a and R 11b One of the groups is H and the other is R 11a and R 11b The other side is R 12a or R 12b together with one of the following to form a cyclopropyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0170] In one aspect, provided herein is a compound of formula (I) or (IA), for example, a compound of formula (I-A1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 5 , R 7 , R 8 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A1) 3 , R 5 , R 7 , R 8 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0171] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 and R 7 are each independently H, halo, or C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 5 and R 7 C 1~6 Each alkyl is independently optionally substituted with one or more halo or CN. In some embodiments, R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN. In some embodiments, R 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, or C1~3 In some embodiments, R 5 and R 7 are each independently H. In some embodiments, R 5 and R 7 One of the groups is H and the other is R 5 and R 7 The other one is independent, halo, C 1~3 Alkyl, or C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0172] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 and R 7 are each H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0173] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is H and R 7 is halo. In some embodiments, R 5 is H and R 7 is F. In some embodiments, R 5 is H and R 7is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0174] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is H and R 7 is C 1~6 In some embodiments, R 5 is H and R 7 is C 1~3 In some embodiments, R 5 is H and R 7 is methyl. In some embodiments, R 5 is H and R 7 is ethyl. In some embodiments, R 5 is H and R 7 is isopropyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0175] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is H and R 7 is C 1~6 In some embodiments, R 5 is H and R 7 is C 1~3 In some embodiments, R5 is H and R 7 is CF3. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0176] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is the halo and R 7 is H. In some embodiments, R 5 is F and R 7 is H. In some embodiments, R 5 is Cl and R 7 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0177] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is C 1~6 alkyl, and R 7 is H. In some embodiments, R 5 is C 1~3 alkyl, and R 7 is H. In some embodiments, R 5 is methyl and R 7 is H. In some embodiments, R 5 is ethyl, and R 7is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0178] In one aspect, the present disclosure provides a compound of formula (I) or (IA), such as a compound of formula (I-A2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 6 , R 7 , R 8 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A2) 3 , R 6 , R 7 , R 8 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0179] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is H or halo, and R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is H or halo, and R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3 The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is H or halo, and R 7 H, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 6 is H or halo, and R 7 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0180] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is H and R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is H and R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is H and R 7 H, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 6 is H and R 7 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0181] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is the halo and R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is the halo and R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3 The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 6 is the halo and R 7 H, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R 6 is the halo and R 7is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0182] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 7 are each H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0183] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is H and R 7 is halo. In some embodiments, R 6 is H and R 7 is F. In some embodiments, R 6 is H and R 7 is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0184] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is H and R 7 is C 1~6 In some embodiments, R 6 is H and R 7 is C 1~3 In some embodiments, R 6 is H and R 7 is methyl. In some embodiments, R 6 is H and R 7 is ethyl. In some embodiments, R 6 is H and R 7 is isopropyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0185] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is H and R 7 is C 1~6 In some embodiments, R 6 is H and R 7 is C 1~3 In some embodiments, R 6 is H and R 7 is CF3. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0186] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 is the halo and R 7 is H. In some embodiments, R 6 is F and R 7 is H. In some embodiments, R 6 is Cl and R 7 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0187] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 7 and each is halo. In some embodiments, R 6 is F and R 7 is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0188] In one aspect, provided herein are compounds of formula (I) or (IA), such as compounds of formula (I-A3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A3) 3 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0189] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CN, and R 9 is H or halo. In some embodiments, R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3 The alkyl is optionally substituted with one or more halo or CN, and R 9 is H or halo. In some embodiments, R 7 H, halo, C 1~3 Alkyl, or C 1~3 haloalkyl, and R 9 is H or halo. In some embodiments, R 7 is H and R 9is H or halo. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0190] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CH, and R 9 is H. In some embodiments, R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3 The alkyl is optionally substituted with one or more halo or CH, and R 9 is H. In some embodiments, R 7 H, halo, C 1~3 Alkyl, or C 1~3 haloalkyl, and R 9 is H. In some embodiments, R 7 is H and R 9 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0191] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CN, and R 9 is halo. In some embodiments, R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3 The alkyl is optionally substituted with one or more halo or CN, and R 9 is halo. In some embodiments, R 7 H, halo, C 1~3 Alkyl, or C 1~3 haloalkyl, and R 9 is halo. In some embodiments, R 7 is H and R 9 is halo. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0192] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 and R 9are each H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0193] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is the halo and R 9 is H. In some embodiments, R 7 is F and R 9 is H. In some embodiments, R 7 is Cl and R 9 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0194] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is C 1~6 alkyl, and R 9 is H. In some embodiments, R 7 is C 1~3 alkyl, and R 9 is H. In some embodiments, R 7 is methyl and R 9 is H. In some embodiments, R 7 is ethyl, and R 9 is H. In some embodiments, R 7 is isopropyl, and R 9is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0195] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is C 1~6 haloalkyl, and R 9 is H. In some embodiments, R 7 is C 1~3 haloalkyl, and R 9 is H. In some embodiments, R 7 is CF3 and R 9 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0196] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 and R 9 and each is halo. In some embodiments, R 7 is Cl and R 9 is F. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0197] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is H and R 9 is halo. In some embodiments, R 7 is H and R 9 is F. In some embodiments, R 7 is H and R 9 is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0198] In one aspect, provided herein is a compound of formula (I) or (IA), such as a compound of formula (I-A4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 5 , R 8 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A4) 3 , R 5 , R 8 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0199] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0200] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is C 1~6 In some embodiments, R 5 is C 1~3 In some embodiments, R 5 is methyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0201] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is halo. In some embodiments, R 5 is F. In some embodiments, R 5 is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0202] In one aspect, provided herein are compounds of formula (I) or (IA), such as compounds of formula (I-A5): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 2 , R 3 , R 7 , R 8 , R 10 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A5) 2 , R 3 , R 7 , R 8 , R 10 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0203] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 H, halo, C 1~6 Alkyl, C 3~10 Cycloalkyl, or C 1~6 haloalkyl, where R 7 C 1~6 The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 7 H, halo, C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 7 C 1~3The alkyl is optionally substituted with one or more halo or CN. In some embodiments, R 7 H, halo, C 1~3 Alkyl, or C 1~3 In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0204] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0205] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is halo. In some embodiments, R 7 is F. In some embodiments, R 7 is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0206] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is C 1~6 In some embodiments, R 7 is C 1~3 In some embodiments, R 7 is methyl. In some embodiments, R 7 is ethyl. In some embodiments, R 7 is isopropyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0207] In some embodiments of a compound of Formula (I) or (IA), e.g., a compound of Formula (I-A5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 is C 1~6 In some embodiments, R 7 is C 1~3 In some embodiments, R 7 is CF3. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0208] In one aspect, provided herein is a compound of formula (I) or (IA), such as a compound of formula (I-A6): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 8 , R 10 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-A6) 3 , R 8 , R 10 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0209] In one aspect, provided herein is a compound of formula (I) or (IA), such as a compound of formula (IB): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and X are as defined for compounds of formula (I). In some variations, m, R of formula (IB) 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0210] In one aspect, provided herein are compounds of formula (I), (IA), or (IB), such as compounds of formula (I-B1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined for compounds of formula (I). In some variations, m, R of formula (I-B1) 3 , R 5 , R 6 , R 7 , R 8 , and R 9 is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0211] In one aspect, provided herein are compounds of formula (I), (IA), or (IB), such as compounds of formula (I-B2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined for compounds of formula (I). In some variations, m, R of formula (I-B2) 3 , R 5 , R 6 , R 7 , R 8 , and R 9is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0212] In one aspect, provided herein are compounds of formula (I), (IA), or (IB), such as compounds of formula (I-B3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined for compounds of formula (I). In some variations, m, R of formula (I-B3) 3 , R 5 , R 6 , R 7 , R 8 , and R 9 is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0213] In some embodiments of a compound of Formula (I), (IA), or (IB), e.g., a compound of Formula (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0214] In some embodiments of a compound of Formula (I), (IA), or (IB), e.g., a compound of Formula (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 12a and R 12b are each independently H or C 1~6 In some embodiments, R 12a and R 12b are each independently H or C 1~3 In some embodiments, R 12a and R 12b are each independently H. In some embodiments, R 12a and R 12b One of them is H and R 12a and R 12b The other is C 1~3 In some embodiments, R 12a and R 12b One of them is H and R 12a and R 12b The other is methyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0215] In one aspect, provided herein are compounds of formula (I), (IA), or (IB), such as compounds of formula (I-B4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 In some variations, m, R in formula (I-B4) are as defined elsewhere herein.3 , R 5 , R 6 , R 7 , R 8 , and R 9 is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0216] In some embodiments of a compound of Formula (I), (IA), or (IB), e.g., a compound of Formula (I-B4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is H. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0217] In some embodiments of a compound of Formula (I), (IA), or (IB), e.g., a compound of Formula (I-B4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is C 1~6 In some embodiments, R 4 is C 1~3 In some embodiments, R 4 is CH3. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0218] In one aspect, provided herein are compounds of formula (I), such as compounds of formula (IC): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I), and p is an integer from 0 to 5. In some variations, m, n, R of formula (IC) a , R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0219] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IC), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0220] In one aspect, provided herein are compounds of formula (I) or (IC), such as compounds of formula (I-C1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-C1) a , R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0221] In some embodiments of a compound of Formula (I) or (IC), e.g., a compound of Formula (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -NH-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0222] In one aspect, provided herein are compounds of formula (I), (IA), or (IC), such as compounds of formula (I-C2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-C2) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0223] In some embodiments of a compound of Formula (I), (IA), or (IC), e.g., a compound of Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R a -OH, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, R a -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, R a is C 1~3 Alkyl or C 1~3 In some embodiments, R a is CH or CF. In some embodiments, R a is CH3. In some embodiments, R a is halo. In some embodiments, R ais Br, Cl, F, or I. In some embodiments, R a is Cl. In some embodiments, R a is F. In some embodiments, R a In some embodiments of a compound of Formula (I), (IA), or (IC), such as a compound of Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R a -OH, oxo, -CN, halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4 to 10 membered heterocyclyl, or C 3~10 cycloalkyl, where R a C 1~6 Alkyl, C 1~6 Alkoxy, 4-10 membered heterocyclyl or C 3~10 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~6 Alkyl, or C 1~6 In some embodiments, R a -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 10-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R bindependently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 In some embodiments, R a -OH, halo, C 1~3 Alkyl, C 1~3 haloalkyl, where R a C 1~3 Alkyl is one or more R b and each R b is, independently at each occurrence, -OH or C 1~3 In some embodiments, R a teeth, [ka] is selected from the group consisting of:

[0224] In some embodiments of a compound of Formula (I), (IA), or (IC), e.g., a compound of Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 In some embodiments, X is —O—, —S—, —C(R alkyl)-. 12a )(R 12b )-, -N(H)-, or -N(C 1~3 In some embodiments, X is -O-. In some embodiments, X is -S-. In some embodiments, X is -NH-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0225] In one aspect, provided herein are compounds of formula (I), (IA), or (IC), such as compounds of formula (I-C3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-C3) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0226] In some embodiments of a compound of Formula (I), (IA), or (IC), e.g., a compound of Formula (I-C2) or (I-C3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —O— and R a is C 1~6 In some embodiments, X is —O— and R a is C 1~3 In some embodiments, X is —O— and R a is methyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0227] In some embodiments of a compound of Formula (I), (IA), or (IC), e.g., a compound of Formula (I-C2) or (I-C3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is —O— and R a In some embodiments, X is —O— and R a is Br, Cl, F, or I. In some embodiments, X is —O— and R a is F. In some embodiments, X is —O— and R a is Cl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0228] In some embodiments of a compound of Formula (I'), (IA), or (IC), e.g., a compound of Formula (I-C2) or (I-C3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is -O- and R a -OH, halo, C 1~6 Alkyl, C 1~6 haloalkyl, where R 5 C 1~6 Alkyl is one or more R b and each R b is, independently at each occurrence, -OH or C 1~6 In some embodiments, X is -O- and R a -OH, halo, C 1~3 Alkyl, C 1~3 haloalkyl, where R a C 1~3 Alkyl is one or more R b and each R b is, independently at each occurrence, -OH or C 1~3 It is an alkoxy.

[0229] In one aspect, provided herein is a compound of formula (I-C4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-C4) 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0230] In one aspect, provided herein is a compound of formula (I-C5): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b are as defined for compounds of formula (I). In some variations, m, n, R of formula (I-C5) 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11bis as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0231] In one aspect, provided herein are compounds of formula (I) or (IA), such as compounds of formula (ID): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, q, r, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I), q is an integer from 1 to 7, and r is an integer from 0 to 18. In some variations, m, n, q, r, R of formula (ID) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0232] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, q is an integer from 1 to 3. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0233] In one aspect, provided herein are compounds of formula (I), (IA), or (ID), such as compounds of formula (I-D1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for compounds of formula (I), and r is an integer from 0 to 6. In some variations, m, n, R of formula (I-D1) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0234] In one aspect, provided herein are compounds of formula (I), (IA), or (ID), such as compounds of formula (I-D2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for compounds of formula (I) and r is an integer from 0 to 8. In some variations, m, n, R of formula (I-D2) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0235] In one aspect, provided herein are compounds of formula (I), (IA), or (ID), such as compounds of formula (I-D3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for compounds of formula (I) and r is an integer from 0 to 10. In some variations, m, n, R of formula (I-D3) a , R 5 , R 6 , R 7 , R 8 , R9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some variations, m, n, R of formula (I-D3) a , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , and R 11b is as defined for a compound of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0236] In one aspect, provided herein is a compound of formula (II), e.g., a compound of formula (I-D1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , and R 11b is as defined for compounds of formula (I), and R 3a is C 1~6 It is alkyl.

[0237] In one embodiment, a compound of formula (I), for example a compound of formula (IE): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 1 , R 3 , R 5, R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined elsewhere herein. In some variations, m, n, R of formula (IE) 1 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0238] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IE), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0 to 4. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0239] In one embodiment, a compound of formula (I) or (IE), for example, a compound of formula (I-E1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R8 , R 9 and X are as defined elsewhere herein. In some variations, m, R in formula (I-E1) 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0240] In one embodiment, a compound of formula (1-E2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined elsewhere herein. In some variations, m, R in formula (I-E2) 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0241] In one embodiment, a compound of formula (1-E3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R 3 , R 5 , R 6 , R 7 , R8 , R 9 and X are as defined elsewhere herein. In some variations, m, R in formula (I-E3) 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0242] In one aspect, provided herein is a compound of formula (IF): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, R of formula (I-E3) 3 , R 5 , R 6 , R 7 , R 8 , R 9 and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0243] In one aspect, provided herein are compounds of formula (IG): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, each R 4 , R 5 , R6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for compounds of formula (I). In some variations, m, n, each R of formula (IG) 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0244] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, each R 4 are independently H, C 1~6 Alkyl, C 1~6 Haloalkyl, or C 3~10 In some embodiments, each R 4 are independently H, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 In some embodiments, each R 4 are independently H or C 1~3 In some embodiments, one R 4 is H and the other R 4 is C 1~3 In some embodiments, one R 4 is H and the other R 4is methyl. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0245] In one aspect, provided herein is a compound of formula (IH): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R 3 , R 5 , R 6 , R 7 , R 9 , R 11a , R 11b , R a and X are as defined for compounds of formula (I), and Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently -C-, -CH-, -CH2-, -N-, -NH-, -S-, or -O-, s is an integer of 0 to 6, and t is 1 or 2; [ka] In some variations, m, n, R in formula (IH) 3 , R 5 , R 6 , R 7 , R 9 , R 11a , R 11b , R a and X are as defined for the compounds of formula (I'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0246] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IH), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 2, n is an integer from 0 to 2, and X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4 ) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 10-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 11a and R 11b is independently H or C at each occurrence 1~3 alkyl or R 12a Or R 12b C together with one of 3~6 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~3alkyl or R 12a and R 12b One of them is H or C 1~3 alkyl, and R 12a and R 12b The other side is R 11a or R 11b Together with C 3~6 form a cycloalkyl, and each R a independently for each occurrence: -OH, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 is cycloalkyl, and Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently -C-, -CH-, -CH2-, -N-, -NH-, -S-, or -O-, s is an integer of 0 to 6, and t is 1 or 2; [ka] represents a single or double bond.

[0247] In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IH), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 2, n is an integer from 0 to 2, and X is —O—, —S—, —C(R 12a )(R 12b )-, -N(H)-, or -N(C 1~6 alkyl)-, and R 3 is C 1~3 Alkyl, C 1~3 Haloalkyl, C 3~6 Cycloalkyl, -N(R 4) 2, or 4- to 6-membered heterocyclyl, where each R 3 is one or more R a and each R 4 are independently H, C 1~3 Alkyl, C 1~3 Haloalkyl, or C 3~6 cycloalkyl, or both R 4 together with the N atoms to which they are attached, form one or more R a and R forms a 4- to 6-membered heterocyclyl optionally substituted with 5 and R 7 are each independently H, halo, or C 1~3 Alkyl, C 3~6 Cycloalkyl, or C 1~3 haloalkyl, where R 5 and R 7 C 1~3 Each alkyl is independently optionally substituted with one or more halo or CN; R 6 and R 9 are each independently H or halo, and R 11a and R 11b is independently at each occurrence H or C 1~3 alkyl, and R 11a and R 11b One of them is H or C 1~6 alkyl, and R 11a and R 11b The other side is R 12a or R 12b C together with one of 3~10 Forms a cycloalkyl, R 12a and R 12b are each independently H or C 1~3 alkyl or R 12a and R 12b One of them is H or C 1~3 alkyl, and R 12a and R 12b The other side is R 11a or R 11b Together with C 3~6 form a cycloalkyl, and each R ais independently for each occurrence -OH, oxo, -CN, halo, C 1~3 Alkyl, C 1~3 Alkoxy, C 1~3 Haloalkyl, -OC 1~3 Haloalkyl, -NH2, -NH(C 1~3 alkyl), -N(C 1~3 alkyl) 2, 4- to 6-membered heterocyclyl, or C 3~6 cycloalkyl, where R a C 1~3 Alkyl, C 1~3 Alkoxy, 4- to 6-membered heterocyclyl, or C 3~6 Cycloalkyl can be one or more R b and each R b independently for each occurrence: -OH, halo, C 1~3 Alkyl, or C 1~3 is alkoxy, and Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently -C-, -CH-, -CH2-, -N-, -NH-, -S-, or -O-, s is an integer of 0 to 6, and t is 1 or 2; [ka] represents a single or double bond.

[0248] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IH), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of the following formula: [ka] In some embodiments, t is 0. In some embodiments, t is 1. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0249] In some embodiments of a compound of Formula (I), e.g., a compound of Formula (IH), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of the following formula: [ka] where q is an integer from 1 to 7 and r is an integer from 0 to 18. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 1 and Y 5 In some embodiments, t is 1 and Y 5 is -C- and Y 1 , Y 2 , Y 3 , and Y 4 any one of is -N-, -NH-, -S-, or -O-; 1 , Y 2 , Y 3 , and Y 4 and the others are each independently -C-, -CH-, or -CH2-. In some embodiments, t is 1 and Y 5 is -C- and Y 1 , Y 2 , Y 3 , and Y 4 any two of are -N-, -NH-, -S-, or -O-, and Y 1 , Y 2 , Y 3 , and Y 4and the others are each independently -C-, -CH-, or -CH2-. In some variations, the embodiments provided herein also apply to any other applicable formula detailed herein, such as compounds of formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0250] In one aspect, provided herein are compounds of formula (I), such as compounds of formula (IA): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, q, r, s, t, R a , R 3 , each R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11a , R 11b , X, Y 1 , Y 2 , Y 3 , Y 4 and Y are as defined elsewhere herein for compounds of formula (II), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), (IH).

[0251] In some embodiments of a compound of Formula (I) or (I'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1. In some embodiments of a compound of Formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-204 in Table 1. In some embodiments of a compound of Formula (I), or a variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-236 in Table 1. In some embodiments of a compound of Formula (I'), or a variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-317 in Table 1. In some embodiments of a compound of Formula (II), or a variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-669 in Table 1.

[0252] Compound names, as well as all intermediates and compounds contained in Table 1, were generated using ChemDraw® Professional software version 17.1.1.0 or Collaborative Drug Discovery Inc. (CDD) CDD Vault update #3.

[0253] We created a KNIME workflow to retrieve structures from the internal ChemAxon compound registry, generate canonical smiles using the RDKit Canon SMILES node, remove stereochemistry using the ChemAxon / Infocom MolConverter node, and name the structures using the ChemAxon / Infocom Naming node. Below are the versions and extensions of the KNIME analysis platform utilized in the workflow. KNIME Analytics Platform 4.2.2 RDKit KNIME Integration 4.0.1.v202006261025 (This extension includes the RDKit Canon SMILES node) ChemAxon / Infocom Marvin extension 4.3.0v202100 (This extension includes the MolConverter node) ChemAxon / Infocom JChem extension 4.3.0v202100 (This extension includes naming nodes) [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9]

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

Table 1-36

Table 1-37

Table 1-38

Table 1-39

Table 1-40

Table 1-41

Table 1-42

Table 1-43

Table 1-44

Table 1-45

Table 1-46

Table 1-47

Table 1-48

Table 1-49

Table 1-50

Table 1-51

Table 1-52

Table 1-53

Table 1-54

Table 1-55

Table 1-56

Table 1-57

Table 1-58

Table 1-59

Table 1-60

Table 1-61

Table 1-62

Table 1-63

Table 1-64

Table 1-65

Table 1-66

Table 1-67

Table 1-68

Table 1-69

Table 1-70

Table 1-71

Table 1-72

Table 1-73

Table 1-74

Table 1-75

Table 1-76

Table 1-77

Table 1-79

Table 1-80

Table 1-81

Table 1-82

Table 1-83

Table 1-84

Table 1-85

Table 1-86

Table 1-87

Table 1-88

Table 1-89

Table 1-90

Table 1-91

Table 1-92

Table 1-93

Table 1-94

Table 1-95

Table 1-96

Table 1-97

Table 1-98

Table 1-99

Table 1-100

Table 1-101

Table 1-103

Table 1-104

Table 1-105

Table 1-106

Table 1-108

Table 1-109

Table 1-110

Table 1-111

Table 1-112

Table 1-113

Table 1-114

Table 1-115

Table 1-116

Table 1-117

Table 1-118

Table 1-119

Table 1-120

Table 1-121

Table 1-123

Table 1-124

Table 1-125

Table 1-126

Table 1-127

Table 1-129

Table 1-131

Table 1-133

Table 1-136

Table 1-137

Table 1-138

Table 1-139

Table 1-141

[0254] In some embodiments, provided herein is a compound of Formula (I') or (I), or a variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from the group consisting of: N-((6-(benzylamino)-1H-indol-2-yl)methyl)propionamide, N-((6-(benzyl(methyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(benzylamino)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, 1-methyl-N-((6-((pyridin-2-ylmethyl)amino)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-(benzyloxy)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-methyl-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((2-methylthiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((5-methyl-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-4-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-7-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-4-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-7-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((7-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((4-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-methylpyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((4-methylthiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(thiophen-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((3-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((6-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((4-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-methylpyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isothiazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(pyridin-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(thiazol-2-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-((4-chlorobenzyl)oxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, 1-methyl-N-((6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyrimidin-2-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyrimidin-5-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyrimidin-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyridin-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(pyridin-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(oxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((5-methylisoxazol-3-yl)methoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-ethyl-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-chloro-6-((5-methylthiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(furan-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(thiophen-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(furan-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(thiazol-4-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isothiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isothiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((4-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((5-(trifluoromethyl)isoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((5-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((5-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(2-(isoxazol-3-yl)ethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, 1-methyl-N-((6-(2-(thiazol-4-yl)ethyl)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(2-(5-methylisoxazol-3-yl)ethyl)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((5-methylisoxazol-3-yl)oxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylazetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)morpholine-4-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)piperidine-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)piperidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-fluoropyrrolidine-1-carboxamide, N-((6-(isothiazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, (N-((5-chloro-6-((5-ethylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-chloro-6-((5-(difluoromethyl)isoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((5-(difluoromethyl)isoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((2-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide formate, N-((5-chloro-6-(2-(5-methylisoxazol-3-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-cyclopropylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-(trifluoromethyl)pyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-isopropylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(isoxazol-3-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, 1-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-methyl-3-((6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)urea, 1-((5-chloro-6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((5-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)piperidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(trifluoromethyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(hydroxymethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-chloro-6-(2-(thiazol-4-yl)ethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(isoxazol-3-yl)ethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(1-(5-methylisoxazol-3-yl)propan-2-yl)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, trans-1-methyl-N-((6-(2-phenylcyclopropyl)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-3-methyl-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(benzyloxy)-3-methyl-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((3-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(benzyloxy)-3-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethyl)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, 1-methyl-N-((6-((5-methylisoxazol-3-yl)methyl)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(2-(methylamino)-2-oxoethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(oxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((5-methyl-1,3,4-thiadiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-((1,2,5-thiadiazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((5-methyl-1,3,4-oxadiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((3-methyl-1,2,4-oxadiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-((1,2,3-thiadiazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((1,3,4-thiadiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((2-methyl-2H-tetrazol-5-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-methylthiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((2-methylthiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((2-methylthiazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, 1-methyl-N-((6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((1,2,5-thiadiazol-3-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((5-ethylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-isopropyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(cyclopentylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((tetrahydrofuran-3-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-(bicyclo[1.1.1]pentan-1-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(2-(isoxazol-3-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(2-(thiazol-4-yl)ethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-(benzofuran-6-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(2-(bicyclo[1.1.1]pentan-1-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((1H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(2-(5-methylisoxazol-3-yl)propyl)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((6-((isoxazol-3-ylmethyl)thio)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-chloro-6-((isoxazol-3-ylmethyl)thio)-1H-indol-2-yl)methyl)-1-methylcyclopropanecarboxamide, N-((5-chloro-6-((3-hydroxybenzyl)oxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)morpholine-4-carboxamide, 3-fluoro-N-((6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((7-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-ethyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-hydroxybenzyl)oxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-isopropyl-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, 1-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-fluoro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-chloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylurea, 1-methyl-3-((6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)urea, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)acetamide N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)acetamide, N-((5-fluoro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((thiazol-4-ylmethyl)amino)-1H-indol-2-yl)methyl)acetamide, 1-fluoro-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-fluorocyclopropane-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-fluorocyclopropane-1-carboxamide, 1-fluoro-N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((6-(isoxazol-3-ylmethoxy)-5-methyl-1H-indol-2-yl)methyl)acetamide, and N-((5-fluoro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(1-hydroxycyclopropyl)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyclopropyl-2-hydroxyacetamide, (S)—N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxybutanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxybutanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxyacetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxyacetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(oxetan-2-yl)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluoro-2-hydroxypropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluoro-2-hydroxypropanamide, (1R,2R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclobutane-1-carboxamide, (1S,2S)-N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclobutane-1-carboxamide N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxy-2-methylpropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-(hydroxymethyl)cyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-hydroxycyclopropane-1-carboxamide, (1R,3R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxycyclobutane-1-carboxamide, (1S,3S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxycyclobutane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(hydroxymethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(hydroxymethyl)cyclopropane-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(oxetan-3-yl)acetamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methyloxetane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)oxetane-3-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-methoxyacetamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methoxyacetamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-3-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methoxyacetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methoxypropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-methoxyacetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-methyloxetane-3-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)oxetane-3-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-cyanooxetane-3-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methyloxetane-3-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(methoxymethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(methoxymethyl)cyclopropane-1-carboxamide, (S)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (R)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (R)—N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-hydroxypropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxybutanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxybutanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(3-methyloxetan-3-yl)acetamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(tetrahydrofuran-3-yl)acetamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(tetrahydrofuran-3-yl)acetamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methoxypropanamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methoxypropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(difluoromethoxy)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(hydroxymethyl)tetrahydrofuran-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-7-oxabicyclo[2.2.1]heptane-1-carboxamide, (1R,2S,4S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide, (1S,2R,4R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-oxabicyclo[2.1.1]hexane-4-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(2-methoxyethoxy)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-oxabicyclo[3.1.0]hexane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-oxabicyclo[2.1.1]hexane-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-4-methylmorpholine-3-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1,4-dioxane-2-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1,4-dioxane-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluorotetrahydrofuran-3-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3,3-difluorotetrahydrofuran-2-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-methyltetrahydrofuran-2-carboxamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-3-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-hydroxypropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(tetrahydrofuran-2-yl)acetamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-2-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-2-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-methoxypropanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-methoxypropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)oxetane-2-carboxamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)tetrahydrofuran-3-carboxamide, N-((5-chloro-6-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-((1,2,4-oxadiazol-3-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-chlorothiophen-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-chlorothiophen-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isothiazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-chlorothiazol-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-chlorothiophen-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((4-chloroisothiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(pyridin-3-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((2-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-methoxyethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(pyridazin-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-cyclopropoxyethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(oxetan-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((6-methoxypyridazin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(trifluoromethoxy)ethoxy)-1H-indol-2-yl)methyl)acetamide, N-((4-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-cyclopropyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-cyclopropyl-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5,7-dichloro-6-((5-methylisoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5,7-dichloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl-d2)acetamide, N-((5,7-dichloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (S)—N-(1-(5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide, (R)—N-(1-(5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((5-(methylthio)-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((6-((1H-indol-6-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((2-chloro-4-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-(trifluoromethyl)isoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide N-((5-chloro-6-((3,3-difluorocyclobutyl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-((5-(trifluoromethyl)isoxazol-3-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(oxetan-3-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((4-fluoropyridin-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylazetidine-1-carboxamide, N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, 3-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-cyclopropyl-1-methylurea, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylazetidine-1-carboxamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylazetidine-1-carboxamide, (S)—N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylazetidine-1-carboxamide, (R)—N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylazetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methoxyazetidine-1-carboxamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-(hydroxymethyl)azetidine-1-carboxamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-(hydroxymethyl)azetidine-1-carboxamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-hydroxyazetidine-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-(hydroxymethyl)azetidine-1-carboxamide, 1-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-ethylurea, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3,3-difluoroazetidine-1-carboxamide, 1-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-(2-fluoroethyl)urea, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluoroazetidine-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluoropyrrolidine-1-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-fluoropyrrolidine-1-carboxamide, 1-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-(2,2-difluoroethyl)urea, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(difluoromethyl)pyrrolidine-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(difluoromethyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyanoazetidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-(difluoromethyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-6-oxa-1-azaspiro[3.3]heptane-1-carboxamide, 3-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-cyclopropyl-1-methylurea, 1-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-(2-methoxyethyl)urea, (R)—N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, (S)—N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, (R)—N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, (S)—N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, (S)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, (R)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-methylpyrrolidine-1-carboxamide, (R)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, (S)—N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylpyrrolidine-1-carboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylazetidine-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylazetidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(methylthio)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(pyrazolo[1,5-a]pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(3,3-difluorocyclobutyl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-cyclobutylethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (S)—N-(1-(5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide, (R)—N-(1-(5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide, (S)—N-((6-((1,4-dioxan-2-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (R)—N-((6-((1,4-dioxan-2-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (S)—N-((5-chloro-6-(2-(tetrahydrofuran-2-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (R)—N-((5-chloro-6-(2-(tetrahydrofuran-2-yl)ethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisothiazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-methylisothiazol-3-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((5-chlorothiazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-(isoxazol-5-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(2-(isoxazol-3-yl)ethyl)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((thiazol-4-ylmethyl)amino)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(oxazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(2-(thiazol-4-yl)ethyl)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(2-(thiazol-4-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((4-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((4-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-3-ethyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((4-methyloxazol-2-yl)methoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((4-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclobutanecarboxamide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclobutanecarboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pivalamide, N-((5-fluoro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, 1-methyl-N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2,2-difluoropropanamide, 2,2-difluoro-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propanamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-cyanoacetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, 1-methyl-N-((6-(oxazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2,2-difluoropropanamide, 2,2-difluoro-N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)propanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyclopropylacetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)isoxazole-3-carboxamide, N-((5-chloro-6-(((5-methylisoxazol-3-yl)methyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((thiazol-4-ylmethyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(2-methoxypropoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-(2-(tetrahydrofuran-2-yl)ethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(2-cyclobutoxyethoxy)-1H-indol-2-yl)methyl)acetamide, N-((6-((1,4-dioxan-2-yl)methoxy)-5-chloro-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((2,2-difluorocyclopropyl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(2-ethoxyethoxy)-1H-indol-2-yl)methyl)acetamide, N-((6-(benzofuran-6-ylmethoxy)-5-fluoro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(benzofuran-6-ylmethoxy)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-chloro-6-((trans)-3-methoxycyclobutoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-((cis)-3-methoxycyclobutoxy)-1H-indol-2-yl)methyl)acetamide, (S)—N-((5-chloro-6-((tetrahydrofuran-3-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, (R)—N-((5-chloro-6-((tetrahydrofuran-2-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, (S)—N-((5-chloro-6-((tetrahydrofuran-2-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((6-(2-(oxazol-4-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(2-(oxazol-4-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-(((5-methylisoxazol-3-yl)methyl)amino)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-fluoro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((5-chloro-6-((thiazol-4-ylmethyl)amino)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-chloro-3-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((3,5-dichloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((3-chloro-5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(thiazol-4-ylmethoxy)-5-(trifluoromethyl)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(oxazol-4-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(methyl-d3)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(methyl-d3)cyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-cyanocyclopropane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyano-2-methylpropanamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-cyanopropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-cyanocyclobutane-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclobutanecarboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopentanecarboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclobutanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-3,3-difluorocyclobutane-1-carboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)cyclopentanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)pivalamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3,3-difluorocyclobutane-1-carboxamide, N-((5-fluoro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-((6-fluoropyridin-2-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-fluoro-6-(oxazol-4-ylmethoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclobutane-1-carboxamide, N-((5-chloro-6-(pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclobutane-1-carboxamide, N-((5-fluoro-6-(pyridin-2-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclobutane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclobutane-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, 1-methyl-N-((6-(2-(thiazol-4-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((6-(2-(isoxazol-3-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluoropropanamide, 2-(azetidin-1-yl)-N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3,3-difluoropropanamide, 1-methyl-N-((6-(2-(oxazol-4-yl)ethyl)-5-(trifluoromethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((4-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, 3,3-difluoro-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propanamide, N-((4-fluoro-6-(isoxazol-3-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, 3,3-difluoro-N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)propanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3,3-difluoropropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(1H-1,2,3-triazol-1-yl)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(1H-pyrazol-1-yl)acetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)isoxazole-5-carboxamide, N-((5-fluoro-6-((thiazol-4-ylmethyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((isoxazol-3-ylmethyl)amino)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((4,5-difluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((4-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propionamide, N-((6-(isoxazol-3-ylmethoxy)-5-methyl-1H-indol-2-yl)methyl)propionamide, N-((5-methyl-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-methyl-1H-indol-2-yl)methyl)azetidine-1-carboxamide, N-((6-(isoxazol-3-ylmethoxy)-5-methyl-1H-indol-2-yl)methyl)pyrrolidine-1-carboxamide, (1R,2R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclopentane-1-carboxamide, (1S,2S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclopentane-1-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxy-2-methylpropanamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3-hydroxy-2-methylpropanamide, (1S,2R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1R,2S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1R,2R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1S,2S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1R,2R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1S,2S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1S,2R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (1R,2S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-fluorocyclopropane-1-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(oxetan-3-yl)propenamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(oxetan-3-yl)propanamide, (R)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methyl-2-oxoazetidine-3-carboxamide, (S)—N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-methyl-2-oxoazetidine-3-carboxamide, N-((5-fluoro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-fluoro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropanecarboxamide, N-((5-fluoro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)propionamide, N-((5-fluoro-6-((2-methyloxazol-4-yl)methoxy)-1H-indol-2-yl)methyl)isobutyramide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)bicyclo[1.1.1]pentane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)spiro[2.2]pentane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3,3,3-trifluoropropanamide, 2-(bicyclo[1.1.1]pentan-1-yl)-N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)bicyclo[2.2.1]heptane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)spiro[3.3]heptane-2-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)spiro[2.3]hexane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-1-(difluoromethyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2,2-difluoroacetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-3-methylcyclobutane-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)acetamide-2,2,2-d3, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2,2-difluoroacetamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-3,3,3-trifluoropropanamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-(difluoromethyl)cyclopropane-1-carboxamide, N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide-2,2,2-d3, 2,2-difluoro-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide, 3,3,3-trifluoro-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)propanamide, 1-(difluoromethyl)-N-((5-fluoro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)acetamide-2,2,2-d3, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-fluorocyclopropane-1-carboxamide, 1-fluoro-N-((5-fluoro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)cyclopropane-1-carboxamide, (1R,2S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclopentane-1-carboxamide, (1S,2R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-hydroxycyclopentane-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methyl-2-oxopyrrolidine-3-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methyl-2-oxopyrrolidine-3-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylazetidine-2-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylazetidine-2-carboxamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylpyrrolidine-2-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-1-methylpyrrolidine-2-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(dimethylamino)acetamide, N-((5-chloro-6-(thiazol-4-ylmethoxy)-1H-indol-2-yl)methyl)-2-(dimethylamino)acetamide, (S)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(difluoromethyl)azetidine-1-carboxamide, (R)—N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-(difluoromethyl)azetidine-1-carboxamide, N-((5-chloro-6-((3-methylisoxazol-5-yl)methoxy)-1H-indol-2-yl)methyl)-2-oxopropanamide, N-((6-(2-(1H-1,2,3-triazol-1-yl)ethyl)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(2-(2H-tetrazol-2-yl)ethyl)-5-chloro-1H-indol-2-yl)methyl)-1-methylcyclopropane-1-carboxamide, N-((6-(2-(1H-tetrazol-1-yl)ethyl)-5-chloro-1H-indol-2-yl)methyl)-1-methylc...

Claims

1. Compound of formula (II): 【Chemical 566】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C １～６ Alkoxy, —C(O)C １～６ Alkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ , 5- to 20-membered heteroaryl, —C １～６ alkyl (5- to 20-membered heteroaryl), or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ and optionally substituted with R ３ is a 6- to 10-membered heteroaryl, the 6- to 10-membered heteroaryl is unsubstituted; Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, —C １～６ alkyl (5-20 membered heteroaryl), or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Thioalkyl, C ３～１０ Cycloalkyl, C １～６ haloalkyl, or 5- to 20-membered heteroaryl, wherein R ５ and R ７ The above C １～６ alkyl, the C １～６ Alkoxy, or the C ３～１０ each cycloalkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C １～６ Alkoxy, C ３～１０ Cycloalkyl, —O—C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, 5- to 20-membered heteroaryl, or -(R ｘ )-5 to 20-membered heteroaryl), where each R ８ is one or more R ａ is optionally replaced by R ｘ is —NH— or —O—, R １０ is, independently at each occurrence, H or D; R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ is alkyl, or R １１ａ and R １１ｂ One of the is H or C １～６ alkyl, and R １１ａ and R １１ｂ The other side is R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with one of the ３～１０ forming a cycloalkyl, Each R ａ are independently D, —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), -C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy.

2. The compound is a compound of formula (I'): 【Chemical 567】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １０ is H, R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ is alkyl, or R １１ａ and R １１ｂ One of the is H or C １～６ alkyl, and R １１ａ and R １１ｂ The other is R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other is R １１ａ Or R １１ｂ Together with one of the ３～１０ forming a cycloalkyl, Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), -C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ The compound of claim 1, wherein:

3. The compound is a compound of formula (I): 【Chemical 568】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １０ is H, R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ alkyl or R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with ３～１０ forming a cycloalkyl, and Each R ａ is independently at each occurrence -OH, halo, C １～６ Alkyl, C １～６ haloalkyl, or C ３～１０ 3. The compound of claim 1 or 2, wherein:

4. 4. The compound of any one of claims 1 to 3, wherein the compound is a compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing: 【Chemical 569】

5. 5. The compound of any one of claims 1 to 4, wherein m is an integer from 1 to 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

6. 6. The compound of any one of claims 1 to 5, wherein m is 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

7. 7. The compound of any one of claims 1 to 6, wherein n is an integer from 0 to 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

8. 8. The compound of any one of claims 1 to 7, wherein n is 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

9. 8. The compound of any one of claims 1 to 7, wherein n is 0, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

10. 9. The compound of any one of claims 1 to 8, wherein m is 1 and n is 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

11. 10. The compound of any one of claims 1 to 7 or 9, wherein m is 1 and n is 0, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

12. R ３ But C １～６ Alkyl, C １～６ Haloalkyl, C １～６ Alkoxy, —C(O)C １～６ Alkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ , 5- to 20-membered heteroaryl, or 4- to 10-membered heterocyclyl, and each R ３ is one or more R ａ 12. The compound of any one of claims 1 to 11, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted by:

13. R ３ is C １～３ 13. The compound of any one of claims 1 to 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R is alkyl.

14. R ３ 14. The compound of any one of claims 1 to 13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein is methyl, ethyl, or isopropyl.

15. R ３ However, one or more R ａ C optionally substituted with １～３ alkyl, and R ａ is -OH, halo, C １～３ Alkoxy, 4- to 6-membered heterocyclyl, or C ３～６ cycloalkyl, where R ａ The above C １～３ alkoxy, the 4- to 6-membered heterocyclyl, or the C ３～６ Cycloalkyl is one or more R ｂ and each R ｂ is independently at each occurrence -OH, halo, C １～３ Alkyl, or C １～３ 15. The compound of any one of claims 1 to 14, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is alkoxy.

16. R ３ but, 【Chemistry 570】 16. The compound of any of claims 1 to 12 or 15, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

17. R ３ However, one or more R ａ C optionally substituted with ３～６ 13. The compound of any one of claims 1 to 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is cycloalkyl.

18. R ３ is one or more of -OH, halo, C １～３ Alkyl, or C １～３ C optionally substituted with haloalkyl ３～６ cycloalkyl, wherein said C １～３ Alkyl is one or more of D, —OH or C １～３ 20. A compound according to any one of claims 1 to 12 or 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted with alkoxy.

19. R ３ but, 【Chemistry 571】 19. The compound of any of claims 1 to 12, 17 or 18, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

20. R ３ But -N(R ４ ) ２ and each R ４ are independently H, C １～３ Alkyl, C １～３ Haloalkyl, —C １～３ alkyl (5-20 membered heteroaryl), or C ３～６ 13. The compound of any one of claims 1 to 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is cycloalkyl.

21. R ３ But -N(R ４ ) ２ and each R ４ are independently H, C １～３ Alkyl, or C １～３ 21. The compound of any one of claims 1 to 12 or 20, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

22. R ３ However, one or more R ａ 13. The compound of any one of claims 1 to 12, wherein R is 4 to 6 membered heterocyclyl optionally substituted by R, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

23. R ３ But -N(R ４ ) ２ and both R ４ together with the N atoms to which they are attached, form one or more R ａ 23. The compound of any one of claims 1 to 12 or 22, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which forms a 4- to 6-membered heterocyclyl optionally substituted by

24. R ３ But -N(R ４ ) ２ and both R ４ together with the N atoms to which they are attached, form one or more R ａ and R ａ OH, CN, halo, C １～６ Alkyl, C １～６ Haloalkyl, C １～６ Alkoxy, or C ３～１０ is cycloalkyl, and R ａ The above C １～６ 24. The compound of claims 1-12, 22, or 23, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein alkyl is optionally substituted with one or more OH.

25. R ３ but, 【Chemical 572】 25. The compound of any of claims 1 to 12 or 22 to 24, or a stereoisomer or tautomer thereof, selected from the group consisting of: or a pharmaceutically acceptable salt of any of the foregoing.

26. R ３ is one or more of -CN, oxo, halo, or C １～３ 4-6 membered heterocyclyl optionally substituted with alkyl, where R ａ The above C １～３ 13. The compound of any one of claims 1 to 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein alkyl is optionally substituted with one or more OH.

27. R ３ but, 【Chemical 573】 27. The compound of any one of claims 1 to 12, 26, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, selected from the group consisting of:

28. R ３ However, one or more R ａ 13. The compound of any of claims 1 to 12, wherein R is 5-membered heteroaryl optionally substituted with R, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

29. R ３ but 【Chemical 574】 29. The compound of any one of claims 1 to 12 or 28, wherein:

30. R ５ and R ７ each independently represents H, halo, or C １～３ Alkyl, C ３～６ cycloalkyl, or C １～３ haloalkyl, where R ５ and R ７ The above C １～３ 30. The compound of any of claims 1-29, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each alkyl is independently optionally substituted with one or more halo or CN.

31. R ５ and R ７ each independently represents H, halo, or C １～３ Alkyl, or C １～３ 31. The compound of any one of claims 1 to 30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is haloalkyl.

32. R ５ and R ７ is each independently H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

33. R ５ and R ７ one of which is H and R ５ and R ７ The other one is independent, halo, C １～３ Alkyl, or C １～３ 32. The compound of any one of claims 1 to 31, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is haloalkyl.

34. R ６ and R ９ is each independently H or halo, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

35. R ６ and R ９ and each are H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

36. R ６ and R ９ is H, and R ６ and R ９ The compound of any one of claims 1 to 34, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the other of

37. R ８ is -C(O)N(R ４ ) ２ , C ３～６ Cycloalkyl, C ６～１２ aryl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, and each R ８ is one or more R ａ 37. The compound of any one of claims 1 to 36, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted by:

38. R ８ is -C(O)N(R ４ ) ２ and each R ４ are independently H, C １～６ Alkyl, C １～６ haloalkyl, or C ３～１０ 38. The compound of any one of claims 1 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is cycloalkyl.

39. R ８ is -C(O)N(R ４ ) ２ and each R ４ are independently H or C １～６ 39. The compound of any one of claims 1 to 38, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R is alkyl.

40. R ８ However, one or more R ａ C optionally substituted with ３～６ 38. The compound of any one of claims 1 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is cycloalkyl.

41. R ８ but, 【Chemistry 575】 41. The compound of any of claims 1 to 37 or 40, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

42. R ８ However, one or more R ａ C optionally substituted with ６～１２ 38. The compound of any one of claims 1 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is aryl.

43. R ８ but, 【Chemical 576】 43. The compound of any of claims 1 to 37 or 42, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

44. R ８ However, one or more R ａ 38. The compound of any one of claims 1 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

45. R ８ but, 【Chemical 577】 45. The compound of any of claims 1 to 37 or 44, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

46. R ８ However, one or more R ａ 38. The compound of any one of claims 1 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

47. R ８ but one or more halo, C １～６ Alkyl, C １～６ haloalkyl, or C ３～１０ 47. The compound of any one of claims 1 to 37 or 46, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is 5 to 10 membered heteroaryl optionally substituted with cycloalkyl.

48. R ８ but, 【Chemical 578】 48. The compound of any one of claims 1 to 37, 46, or 47, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

49. R １１ａ and R １１ｂ is each independently at each occurrence H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

50. R １１ａ and R １１ｂ is H, and R １１ａ and R １２ｂ The other one is C １～３ 49. The compound of any one of claims 1 to 48, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R is alkyl.

51. R １１ａ and R １１ｂ is H, and R １１ａ and R １２ｂ 51. The compound of any one of claims 1 to 48 or 50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the other of

52. 52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is -O-.

53. 52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is -S-.

54. X is -C(R １２ａ ) (R １２ｂ 52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

55. X is -C(R １２ａ ) (R １２ｂ )-, n is 0, and R ８ Ga-(R ｘ 52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23

56. X is -CH ２ - or -CH(C １～６ 55. The compound of any one of claims 1 to 51 or 54, wherein R is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 39, 39, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66

57. X is -N(R １２ 52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

58. 57. The compound of any one of claims 1 to 51 or 56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is -NH-.

59. n is 1 and R １２ａ and R １２ｂ One of the １～６ alkyl, and R １２ａ and R １２ｂ The other one is R １１ａ or R １１ｂ Together with ３～１０ 52. The compound of any one of claims 1 to 51, which forms a cycloalkyl.

60. The compound is a compound of formula (IC): 【Chemical 579】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and p is an integer from 0 to 5; or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

61. The compound is a compound of formula (ID): 【Chemistry 580】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, q is an integer from 0 to 7, and and r is an integer from 0 to 19; or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

62. The compound is a compound of formula (I-H): 【Chemistry 581】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, s is an integer from 0 to 6; t is 1 or 2, and 【Chemistry 582】 represents a single bond or a double bond, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

63. The compound has the formula: 【Chemistry 583】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

64. 2. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1 to 669 in Table 1.

65. 65. A process for preparing a compound of formula (I') as defined in any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising: (a) Compound of formula (I'-1): 【Chemical 584】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q １ is a halo, boronic acid, or boronic ester; PG is absent or is a protecting group; m is an integer from 1 to 4, R １ is —N—, —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R １０ is H, and Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), —C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. with a compound of formula (I'-2): 【Chemistry 585】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y １ is H, hydrazone, boronic acid, boronic ester, or halo; n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ alkyl or R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with ３～１０ forming a cycloalkyl, and Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), -C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. in the presence of one or more coupling reagents to produce a compound of formula (I'-3): 【Chemistry 586】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, PG is absent or is a protecting group; m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —N—, —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １０ is H, R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ alkyl or R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with ３～１０ forming a cycloalkyl, Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), —C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. and then (b) optionally contacting said compound of formula (I'-3) with a deprotecting agent, providing a compound of formula (I').

66. 66. The process of claim 65, wherein the protecting group is a tert-butoxy group.

67. 67. The process of claim 65 or 66, wherein the one or more coupling reagents comprise one or more reagents selected from the group consisting of a palladium catalyst, a phosphine ligand, and a base.

68. 68. The process of any of claims 65 to 67, wherein the deprotecting agent comprises an acid.

69. 65. A process for preparing a compound of formula (I') as defined in any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising: (a) Compound of formula (IV'-1): 【Chemistry 587】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, PG is absent or is a protecting group; Q ２ is H or (=O), m is an integer from 1 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —N—, —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R １０ is H, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, and Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), -C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. with a compound of formula (II'-2): 【Chemistry 588】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y ２ is OH, (=O), halo, triphenylphosphonium salt, or sulfonate ester; n is an integer from 0 to 4, and R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ is alkyl, and Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), —C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. in the presence of one or more coupling reagents to produce a compound of formula (I'-3): 【Chemistry 589】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, PG is absent or is a protecting group; m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —N—, —NH—, —O—, or —S—, R ２ is H, R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １０ is H, R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ alkyl or R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with ３～１０ forming a cycloalkyl, Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), -C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. and then (b) optionally contacting said compound of formula (I'-3) with a deprotecting agent, providing a compound of formula (I').

70. 70. The process of claim 69, wherein the protecting group is absent.

71. 70. The process of claim 69, wherein the protecting group is mesylate or tosylate.

72. 72. The process of any one of claims 69 to 71, wherein the compound of formula (IV'-1) is an amine, the compound of formula (II'-2) is an aldehyde or ketone, and the reaction is reductive amination.

73. The process according to any one of claims 69 to 71, wherein the compound of formula (IV'-1) is a phenol or a thiol, the compound of formula (II'-2) is an alkyl halide or a sulfonate ester, and the reaction is an alkylation reaction.

74. 74. The process of claims 69 or 71-73, wherein the deprotecting agent comprises Mg.

75. 65. A process for preparing a compound of formula (I') as defined in any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising: Compound of formula (III'-1): 【Chemistry 590】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q ３ is H, m is an integer from 1 to 4, n is an integer from 0 to 4, X is -O-, -S-, -C(R １２ａ ) (R １２ｂ )-, -N(H)-, or -N(C １～６ alkyl)-, R １ is —NH—, —O—, or —S—, R ２ is H, Each R ４ are independently H, C １～６ Alkyl, C １～６ Haloalkyl, or C ３～１０ is cycloalkyl, or Both R ４ together with the N atoms to which they are attached, form one or more R ａ forming a 4- to 10-membered heterocyclyl optionally substituted with R ５ and R ７ are each independently H, halo, C １～６ Alkyl, C １～６ Alkoxy, C ３～１０ cycloalkyl, or C １～６ haloalkyl, where R ５ and R ７ The above C １～６ each alkyl is independently optionally substituted with one or more halo or CN; R ６ and R ９ are each independently H or halo; R ８ is -C(O)N(R ４ ) ２ , C ３～１０ Cycloalkyl, C ６～２０ aryl, 3- to 10-membered heterocyclyl, or 5- to 20-membered heteroaryl, where each R ８ is one or more R ａ is optionally replaced by R １０ is H, R １１ａ and R １１ｂ is independently at each occurrence H or C １～６ alkyl or R １２ａ Or R １２ｂ Together with one of the ３～１０ forming a cycloalkyl, R １２ａ and R １２ｂ are each independently H or C １～６ is alkyl, or R １２ａ and R １２ｂ One of the is H or C １～６ alkyl, and R １２ａ and R １２ｂ The other side is R １１ａ Or R １１ｂ Together with ３～１０ forming a cycloalkyl, and Each R ａ are independently —OH, oxo, —CN, halo, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, —O—C １～６ Haloalkyl, —NH ２ , —NH(C １～６ alkyl), -N(C １～６ alkyl) ２ , —C(O)NH ２ , -C(O)NH(C １～６ alkyl), —C(O)N(C １～６ alkyl) ２ , 4- to 10-membered heterocyclyl, C ３～１０ cycloalkyl, or —O—C ３～１０ cycloalkyl, where R ａ The above C １～６ alkyl, the C １～６ alkoxy, the 4- to 10-membered heterocyclyl, the C ３～１０ cycloalkyl, or the aforementioned —O—C ３～１０ Cycloalkyl is one or more R ｂ is optionally replaced by, and Each R ｂ are independently D, —OH, halo, C １～６ Alkyl, or C １～６ is an alkoxy group. with a compound of formula (III'-2): 【Chemistry 591】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y ３ is —C(O)OH or —C(O)-halo; R ３ is C １～６ Alkyl, C １～６ Haloalkyl, C ３～１０ cycloalkyl, —N(R ４ ) ２ or 4- to 10-membered heterocyclyl, where each R ３ is one or more R ａ is optionally replaced by, and Each R ａ is independently at each occurrence -OH, halo, C １～６ Alkyl, C １～６ haloalkyl, or C ３～１０ is cycloalkyl] in the presence of one or more coupling reagents to provide a compound of formula (I').

76. 76. The process of claim 75, wherein the one or more coupling reagents comprise one or more reagents selected from the group consisting of HATU and DIEA.

77. 65. A pharmaceutical composition comprising: (i) a compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (ii) one or more pharmaceutically acceptable excipients.

78. A method for modulating SLC6A19 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or to a pharmaceutical composition of claim 77.

79. A method for inhibiting SLC6A19 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or to a pharmaceutical composition of claim 77.

80. 78. A method of reducing systemic phenylalanine, tyrosine, glutamine, or glycine levels in an individual in need thereof, comprising administering to said individual an effective amount of a compound of any of claims 1-64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 77.

81. 78. A method of treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to said individual a compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 77.

82. 82. The method of claim 81, wherein the disease, disorder, or condition is selected from the group consisting of phenylketonuria (PKU), chronic kidney disease (CKD), metabolic syndrome, metabolic disease, hyperphenylalaninemia, tyrosinemia (Type I, II, or III), nonketotic hyperglycinemia, isovaleric acidemia, methylmalonic acidemia, propionic acidemia, maple syrup urine disease, DNAJC12 deficiency, urea cycle disorders, hyperammonemia, diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity-related disorders, and neurodevelopmental disorders and autism spectrum disorders.

83. 83. The method of claim 81 or 82, wherein the disease, disorder, or condition is selected from the group consisting of phenylketonuria (PKU), chronic kidney disease (CKD), metabolic syndrome, and metabolic disease.

84. 82. The method of claim 81, wherein the disease, disorder, or condition is associated with abnormalities in amino acid levels.

85. 83. The method of claim 81 or 82, wherein the disease, disorder, or condition is associated with a genetic deficiency of phenylalanine hydroxylase.

86. 86. The method of any of claims 81-85, wherein an effective amount of the compound is administered.

87. The method of any one of claims 81 to 86, wherein the individual is a human.

88. 77. A kit comprising: (i) a compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77; and (ii) instructions for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

89. 89. The kit of claim 88, wherein the disease, disorder, or condition is associated with abnormalities in amino acid levels.

90. 90. The kit of claim 88 or claim 89, wherein the disease, disorder, or condition is associated with a genetic deficiency of phenylalanine hydroxylase.

91. 89. The kit of claim 88, wherein the disease, disorder, or condition is selected from the group consisting of phenylketonuria (PKU), chronic kidney disease (CKD), metabolic syndrome, metabolic disease, hyperphenylalaninemia, tyrosinemia (Type I, II, or III), nonketotic hyperglycinemia, isovaleric acidemia, methylmalonic acidemia, propionic acidemia, maple syrup urine disease, DNAJC12 deficiency, urea cycle disorders, hyperammonemia, diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity-related disorders, and neurodevelopmental disorders and autism spectrum disorders.

92. 89. The kit of claim 88, wherein the individual has a genetic deficiency of phenylalanine hydroxylase.

93. A compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, for use in modulating SLC6A19 in a cell.

94. A compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, for use in inhibiting SLC6A19 in a cell.

95. 78. A compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, for use in reducing systemic phenylalanine, tyrosine, glutamine, or glycine levels in an individual in need thereof.

96. 78. A compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

97. A compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, for use in modulating SLC6A19 in a cell.

98. 78. Use of a compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, in the manufacture of a medicament for use in inhibiting SLC6A19 in a cell.

99. 78. Use of a compound of any of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 77, in the manufacture of a medicament for use in reducing systemic phenylalanine, tyrosine, glutamine, or glycine levels in an individual in need thereof.

100. 78. Use of a compound according to any one of claims 1 to 64, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 77, in the manufacture of a medicament for use in treating an SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

Images